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ABSTRACT 
The systemic amyloidoses are a diverse collection of multi-organ diseases that 
feature misfolding and aggregation of an amyloidogenic protein leading to the shared, 
common manifestation of extracellular tissue amyloid fibril deposition. As the 
pathologic mechanisms are complex, molecular, biochemical and biophysical studies of 
these disease processes are needed to identify factors other than the amyloidogenic 
protein that may be important. The investigations presented in this thesis have explored 
the involvement of clusterin (CLU), a plasma protein, in transthyretin (TTR) and 
immunoglobulin light chain (LC) forms of systemic amyloidosis. CLU, ubiquitous in 
biological fluids, is an extracellular chaperone that is related to heat shock proteins. We 
hypothesized that CLU is part of a proteostatic mechanism to remove TTR or LC proteins 
from circulation by complexing with these amyloidogenic proteins to prevent proteotoxic 
stresses. Further, we posited that certain aspects of CLU biology, genetics, and 
biochemistry could be exploited for diagnostic or therapeutic strategies in the systemic 
amyloidoses. Analyses of amyloid deposits in SSA (senile systemic amyloidosis), ATTR 
v 
(familial TTR-related amyloidosis), and AL (primary LC amyloidosis) tissues was 
accomplished using light and electron microscopic techniques. Results of these studies 
indicated that CLU is a component of TTR and LC amyloid deposits. The potential of 
CLU as a biomarker for amyloidosis was also investigated; plasma circulating CLU 
levels in patient sera was measured for correlation with disease status and CLU genetic 
variation within our patient population. To investigate the underlying biophysical and 
biochemical associations of CLU with amyloid fibril proteins, we purified CLU from 
pooled human serum and tested the ability of the protein to bind, stabilize, and prevent 
TTR misfolding and amyloid fibril formation. Direct binding of CLU to TTR oligomers 
was demonstrated using surface plasmon resonance. As observed by circular dichroism 
spectroscopy, CLU was capable of stabilizing TTR secondary structure. By quantitative 
Congo red binding, we showed that CLU inhibited TTR amyloid fibril formation. 
Together, these results provide evidence that CLU is a common element of SSA, A TTR, 
and AL amyloidosis pathology, can function as a circulating molecular chaperone, and is 
part of a proteostatic mechanism in amyloid fibril formation. 
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Chapter 1. Introduction 
1.1 Protein Misfolding and Deposition Diseases 
Protein misfolding and aggregation are recognized as critical processes in the 
pathogenesis of a wide range of human diseases. In particular, the deposition of 
aberrantly folded and self-associated proteins as highly organized ~-sheet structured 
amyloid fibrils is the hallmark in a diverse group of diseases known as the amyloidoses. 
More than 25 separate proteins have been identified as amyloidogenic; these proteins 
form the insoluble amyloid fibrils which are deposited either locally at a single site or 
systemically at multiple sites throughout the body (Picken, 2010; Westermark et al., 
2007). Amyloid fibrils bind Congo red dye, producing a characteristic apple-green 
birefringence when viewed microscopically using polarized light. In addition to the fibril 
protein, amyloid deposits have been shown to include a variety of accessory proteins and 
molecules including serum amyloid P, apolipoprotein E, collagen, and 
glycosaminoglycans (GAGs) (Bellotti et al. , 2007). The complexity of amyloid deposits 
in fat and other tissues has been demonstrated over the years and more recently in 
proteomic studies (Kisilevsky, 2000; Lavatelli et al. , 2008; Tennent et al., 1995). 
The wide diversity of protein misfolding and deposition diseases includes 
neurodegenerative disorders such as Alzheimer' s disease (AD) and Parkinson's disease 
(PD) as well as the systemic amyloidosis disorders. In this latter group, the formation of 
extracellular proteinaceous deposits composed of insoluble fibrillar aggregates, termed 
amyloid, is featured and involves common pathological manifestations. The 
pathophysiological mechanism of amyloid fibrillogenesis is thought to involve the 
1 
formation of soluble, toxic, misfolded protein aggregates. It has become increasingly 
evident with recent progress in the exploration of all protein misfolding diseases that 
there may be underlying physiochemical and biochemical origins common to this diverse 
group of pathologies (Chiti and Dobson, 2006). Studies have demonstrated that 
misfolded protein aggregates of both extracellular deposits and intracellular inclusions 
share a common fibrillar structure and morphological characteristics. These fmdings 
suggest that investigations and discovery in each of the misfolding diseases are 
fundamental and may have a broader context in deciphering the pathophysiology of these 
diseases (Chiti and Dobson, 2006). 
1.2 Amyloid 
In 1854, the pathologist, Rudolph Virchow, observed and reported fmding 'waxy' 
material in autopsied livers that displayed unique staining properties with iodine and 
sulfuric acid, the chemical testing indicative of starch (Virchow, 1854). He coined the 
term 'amyloid' to describe these unique tissue deposits. Amyloid fibrils are primarily 
proteinaceous in composition, but are found associated with carbohydrates (GAGs) in 
tissues. A variety of peptides and proteins, independent of amino acid sequence, can 
form highly ordered fibrillar aggregates having the cross-~ sheet structure (Figure lA) 
characteristic of amyloid and displaying a binding affinity for, and the monochromatic 
characteristics of, certain dyes. Of these dyes, Congo red (CR) binds to all amyloid 
fibrils and staining of amyloid deposits will appear red under normal light microscopy 
2 
Figure 1. Amyloid fibril ultrastructure and Congo red histology. 
(A) X-ray diffraction pattern of an amyloid fibril. A fibril modeled by protofilament 
composition, and cross-~ sheet structure is also shown. Reproduced with permission 
from Merlini G, Bellotti V, NEJM, 349:583 (2003), Copyright Massachusetts Medical 
Society. (B) Congo red stained liver tissue demonstrating amyloid infiltration by 
standard light microscopy (x40) and (C) green birefringence under polarized light (x40). 
3 
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(Figure lB). Moreover, CR treatment of tissue infiltrated by amyloid will exhibit a 
unique apple-green birefringence when viewed under polarized light (Figure lC) (Falk et 
al., 1997). In fact, biopsy proof of amyloid by CR staining of is the current diagnostic 
mainstay for amyloid disease identification. The unique histology of amyloid tissue 
treated with CR is believed to result from the intercalation and stacking of the planar 
aromatic rings of the dye between the ~-sheets of amyloid fibrils; in addition to 
birefringence, this binding of CR to amyloid fibrils can also be monitored by 
fluorescence (Giorgadze et al., 2004; Marcus et al., 2012). 
While all amyloid deposits are Congophillic, there is some heterogeneity of fibril 
structure (Chiti and Dobson, 2006). Though the fibril core structures have similar 
features primarily dictated by the intrinsic conformational preferences of the polypeptide 
chain, there are differences in ~-strand length, antiparallel or parallel arrangement, 
number of ~-sheets in the protofilament, and exact spacing between ~-sheets. These 
variations in fibrillar architecture are attributed, in part, to the affect of amino acid side 
chain interactions (Chiti and Dobson, 2006). 
Amyloid fibril formation is hypothesized to be a sequential process initiated by 
the loss of native structure in the amyloidogenic protein precursor (Azevedo et al., 2011; 
Blancas-Mejia and Ramirez-Alvarado, 2013). In the systemic amyloidoses, the majority 
of precursor proteins are derived from plasma, including transthyretin, immunoglobulin 
light chains, fibrinogen, and apolipoprotein AI. At present, the widely accepted model of 
amyloid fibril formation involves a multistage process in which a protein becomes 
structurally destabilized and transitions from a natively folded state to a conformation in 
5 
which hydrophobic regions (normally buried within the core of the protein) become 
exposed (Chiti and Dobson, 2006; lnvernizzi et al., 2012; Rodrigues et al., 2010). The 
misfolded or unfolded state leads to an increased propensity for self-aggregation. In vitro 
studies suggest that aggregation and amyloid fibril growth occur initially through a 
nucleation mechanism which is the rate limiting step in the process. The lag phase, 
which is consistent with protein nucleation, (Invernizzi et al., 2012; Naiki and Nagai, 
2009) is followed by a rapid fibrillization phase (Figure 2). 
During the lag phase, the destabilized amyloid precursor protein is thought to 
transition through a series of non-native structural conformations (Chiti and Dobson, 
2006; lnvernizzi et al., 2012; Rodrigues et al., 2010). These may include pre-fibrillar 
aggregates or o1igomers consisting of multiple misfolded amyloid protein subunits 
(Figure 3); there is an increasing body of evidence indicating that these oligomeric 
intermediates are cytotoxic (Friedman, 2011; Invernizzi et al., 2012; Lambert et al., 
1998). Oligomeric spherical beads, beaded chains, and annular ring structures have all 
been identified as intermediate forms in in vitro amyloid fibril formation studies using 
amyloid beta protein (A~), a-synuclein, amylin, immunoglobulin light chain, 
transthyretin, polyQ-containing proteins, and ~2-microglobulin (Chiti and Dobson, 
2006). Furthermore, there is strong supporting evidence for pre-amyloid oligomer 
cytotoxicity from several in vivo studies showing that severity of cognitive impairment 
in AD was correlated with levels of low molecular weight forms (aggregates) of A~, but 
not with total amyloid burden (Lue et al., 1999; McLean et al., 1999; Wang eta/., 1999). 
6 
Figure 2. Energy diagram of amyloid fibril formation model. 
Stages for amyloid fibrillogenesis include (A) nucleus formation and (B) fibril extension. 
Reproduced with permission from Naiki H, Nagai Y J Biochem. 126(6)751-756 (2009), 
Copyright Oxford University Press. 
7 
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Figure 3. Amyloid protein conformational transitions during fibrillogenesis. 
Reproduced with permission from Chiti F, Dobson CM Annu. Rev. Biochem. 75:333-
66.(2006) , Copyright Annual Reviews. 
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It has also been reported that aggregates of transthyretin (TTR) mutants, associated with 
familial amyloidotic polyneuropathy (F AP), are toxic to neuronal cells whereas the 
native tetrameric form and TTR amyloid fibrils are not (Reixach eta!., 2004; Sorgjerd et 
al., 2008; Sousa et al., 2001). Similar data have demonstrated cardiotoxicity by 
oligomeric LC aggregates (Brenner et al., 2004); cytotoxicity has been demonstrated to 
be mediated by p38 (Shi et al., 2010). 
It is not known whether in vivo oligomer cytotoxicity is solely a result of amyloid 
protein aggregation or mediated by interactions with cellular or extracellular components 
in the crowded biological environment. The presence of a higher proportion of exposed 
hydrophobic residues in the amyloidogenic, non-native precursor protein may trigger a 
cascade of interactions with other biomolecules that are in close proximity. For example, 
it has been demonstrated that mutant TTR aggregates readily bind to plasma membranes, 
increasing membrane fluidity (Hou et al., 2005). Interestingly, Hou et al. reported that 
membrane binding, changes in membrane fluidity, and neuronal cytotoxicity were all 
correlated with the propensity for TTR variant to form aggregations, i.e. L55P > V30M > 
wild-type. Such actions could cause the disruption of critical cellular processes such as 
axonal transport, oxidative stress management, and ion balance resulting in catastrophic 
consequences including cell death. 
1.3 Transthyretin-associated Forms of Amyloidosis 
The classification of amyloid disease type is based on the biochemical identity of 
the protein in the deposits. In the systemic amyloidoses, proteins that can misfold, 
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aggregate, and form amyloid deposits in the heart and other organs include large plasma 
proteins like TTR, immunoglobulin light chain (LC), apolipoprotein AI and All, 
lysozyme, fibrinogen Aa, and gelsolin (Dubrey et al., 2011). In the most common form 
of AL or primary amyloidosis, clonal LC monomers and fragments are components of the 
fibrils. The TTR-associated forms of amyloidosis include inherited and acquired types; 
in familial transthyretin (ATTR) amyloidosis, a point mutation in the TTR gene results in 
expression of an amyloidogenic mutant protein, and in senile systemic amyloidosis 
(SSA), wild-type TTR forms the amyloid fibril deposits (Ruberg and Berk, 2012). While 
the systemic amyloidoses are multiorgan diseases, a frequent and pronounced phenotype 
is a restrictive cardiomyopathy (CMP) that may present clinically as congestive heart 
failure, arrhythmias, or sudden death (Dubrey et al., 2011; Hassan et al., 2005; Ruberg 
and Berk, 2012; Sawyer and Skinner, 2006; Shi et al., 2010). 
ATTR amyloidosis is the most commonly occurring hereditary systemic 
amyloidosis. This disease, inherited in an autosomal dominant manner, is associated with 
more than 100 variants of the plasma protein, TTR. The amyloidogenic mutants, each 
arising from a point mutation in the TTR gene, have amino acid substitutions that cause 
destabilization of the native tetrameric structure of the protein (Connors et al., 2003). 
ATTR amyloidosis is thought to be a rare disease with an estimated incidence of less than 
I per 100,000. However, ATTR amyloidosis associated with the variant, V122I, and 
featuring late onset cardiomyopathy, has a carrier frequency that may be as high as 4 
percent in the U.S. black population (Jacobson et al., 1997). Another of the most 
common ATTR-associated variants is V30M which is prevalent among kindreds in 
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Portugal and Japan (Saraiva et al., 1983; Tawara et al., 1983). In addition, ATTR-V30M 
amyloidosis has been reported in Sweden, where 3% of the population may be 
heterozygous for the mutation (Merlini and Westermark, 2004). 
Patients with ATTR amyloidosis usually present with symptoms of peripheral or 
autonomic neuropathies and/or cardiomyopathy (Adams et al., 2012). Interestingly, 
certain TTR variants consistently feature cardiomyopathy or neuropathy as the dominant 
clinical feature; historically, familial amyloid cardiomyopathy (FA C) or familial amyloid 
polyneuropathy (F AP) has also been used to describe the disease in such cases, most 
notably in patients with ATTR-V122I or -V30M amyloidosis (Merlini and Westermark, 
2004). Peripheral neuropathic involvement usually includes symptoms of lower 
extremity sensory and motor neuropathy with progression over time to the upper 
extremities characterized by a loss of pam and thermal sensations (Merlini and 
Westermark, 2004). Autonomic neuropathy includes gastrointestinal symptoms of 
diarrhea, weight loss, and orthostatic hypotension. Cardiomyopathy presents as 
congestive heart failure (CHF), arrhythmia, and/or conduction disturbances. 
SSA, another systemic amyloidosis associated with TTR, is an age-related and 
acquired form resulting from amyloid fibril deposition of wild-type protein. Autopsy 
studies suggest that SSA may affect as many as one-quarter of all Caucasian males over 
the age of 80 years; as such, this may be a highly prevalent systemic form of amyloidosis 
in the western world (Merlini and Westermark, 2004; Tanskanen et al., 2008). SSA is 
characterized as a slowly progressing disease that mainly features cardiac involvement. 
Over time, pronounced cardiac amyloid infiltration can occur which leads to 
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cardiomegaly. Symptoms include CHF, arrhythmia, and conduction system disturbances 
(Merlini and Westermark, 2004). Due to the advanced age of afflicted patients and the 
occurrence of other cardiovascular diseases, a diagnosis of SSA may frequently be 
overlooked; thus, we suspect that SSA is a disease that is under-diagnosed. Interestingly, 
SSA seems to feature CMP almost exclusively in elderly males and the majority of 
patients diagnosed at our clinic are men over the age of 60 years. 
1.4 Transthyretin 
Transthyretin, previously named prealbumin for its greater electrophoretic 
mobility, circulates as a homotetrameric protein (Mr 56,000) found in plasma and 
cerebrospinal fluid (Figure 4). TTR is synthesized mainly by the liver and choroid 
plexus, but expression also occurs in the retinal epithelium and pancreas. The half-life of 
TTR is relatively short, i.e. < 24 hours, and normal plasma circulating concentrations 
range between 0.2-0.4 mg/mL. 
TTR is known to function as a mmor earner of thyroxine, transporting 
approximately 15% of total plasma thyroxine (T4); two binding pockets for the hormone 
are located at the interfaces of the four TTR subunits (Figure 4). Retinol is also 
transported by TTR through a ternary complex formed with retinol binding protein 
(Schreiber and Richardson, 1997; Shoji and Nakagawa, 1988). However, in plasma, the 
majority of TTR circulates ligand-free, as only a fraction is bound to thyroxine and the 
molar ratio of RBP:TTR is normally 0.3 (Johnson et al., 2012). Many small polycyclic 
aromatic hydrocarbon molecules of diverse structures, e.g. tetrahydroquinoline and 
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Figure 4. Ribbon structure model of transthyretin tetramer. 
Each monomer contains 8 beta sheet strands (A-H) and the subunits are packed together 
as associated dimers indicated as lighter and darker shades of blue. Amino acid residue 
positions for V30A (Val30Ala) and V1221 (Val122lle), two mutants associated with 
cardiac amyloidosis, are shown with red arrows. Thyroxine-binding pockets are 
indicated by green arrows. The intrinsically high ~-sheet content of each monomer 
contributes to the amyloidogenic propensity of the protein. 
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flavones molecules, are capable of binding to TTR in the thyroxine-binding pockets; 
these interactions act to stabilize the native quaternary structure of TTR (Figure 5) 
(Buxbaum and Reixach, 2009). One such compound that stabilizes tetrameric TTR in 
this manner is diflunisal, a non-steroidal anti-inflammatory drug (NSAID) which is 
currently being used in clinical trial at our institution (Figure 5B) (Berk et al., 2012; 
Kingsbury et al., 2008). 
Single amino acid changes in the subunits of TTR can perturb the native fold of 
the protein and destabilize the tetramer, making it prone to dissociation, monomer 
unfolding, and aggregation (Jiang et al., 2001a; Lai et al., 1996; Quintas et al., 2001). 
TTR amyloidogenesis begins with the rate limiting step of tetramer dissociation (Figure 
6). Further unfolding of the monomers to multiple non-native state conformations 
initiates the nucleation phase where misfolded TTR subunits self-associate to form high 
molecular weight (HMW) aggregates or oligomers. Oligomerization continues until 
protofibrils are generated; several protofibrils bundle together to form a mature amyloid 
fibril. 
1.5 Amyloidogenesis - Role of Chaperones 
In vivo, the intra- and extra-cellular maintenance of proper protein folding and the 
prevention of aggregation are facilitated by chaperones. The native conformational states 
and proper functioning of proteins are constantly challenged by physical, metabolic, and 
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Figure 5. Small molecules that bind to transthyretin. 
TTR-binding molecules (A) L-thyroxine, (B) diflunisal, (C) and resveratrol all share 
similar 3-D aromatic structures. 
18 
B 
19 
Figure 6. Transthyretin amyloid fibril formation hypothesis. 
The rate limiting step for TTR amyloid fibril formation is the initial loss of quaternary 
structure and tetramer dissociation. The energy barrier to tetramer dissociation and 
monomer unfolding is lower for TTR pathologic variants compared to the wild-type form 
as amino acid substitutions cause destabilization of native structure. Nucleation of 
misfolded monomers to form high molecular weight (HMW) oligomers followed by 
conformational conversion of these aggregates to protofibrils and fibrils constitute later 
and end stages of TTR amyloid fibril formation. 
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environmental stresses. Loss of protein homeostasis due to these challenges can lead to 
unfolding, misfolding, and aggregation. The inherent plasticity and unstructured nature 
of most proteins requires macromolecular assistance to prevent aggregation and ensure 
proper functioning (Powers et al., 2009). The concept of protein homeostasis or 
proteostasis contends that networks are in place to maintain a properly folded proteome 
(Figure 7), control the rate of protein synthesis, influence the rate of proteome folding, 
prevent aggregation, and mediate degradation allowing efficient protein turnover (Powers 
et al., 2009). Undoubtedly these networks are influenced by well-known cell signaling 
pathways, such as the heat shock response pathway, clearly defmed to maintain protein 
structure-function and prevent aggregation in the face of various stresses. In ATTR 
amyloidosis, which features misfolding of a mutant TTR, the heat shock response 
pathway may be important (Santos SD et al., 2008). Increased expression of heat shock 
proteins Hsp27, Hsp70, and heat shock transcription factor 1 (HSP 1) were reported in 
TTR aggregate positive tissues from human F AP nerve, skin, and salivary gland biopsies, 
TTR-V30M mouse model salivary glands, and neuroblastoma cell cultures treated with 
TTR aggregates (Santos SD et al. , 2008). 
1.6 Clusterin - An Extracellular Chaperone 
Recently, extracellular chaperones have been proposed as components of a quality 
control system that facilitates removal of circulating misfolded proteins and as such, may 
play a role in the pathophysiology of amyloidosis and other protein deposition diseases 
(Wilson et al., 2008). Clusterin (CLU), also called apolipoprotein J, is a ubiquitous 
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Figure 7. Proteostasis network model and biological pathways for unfolded 
proteins. 
The schema illustrates multiple pathways and regulation points at which biological 
systems can maintain proteostasis. Imbalances in this network have been proposed to 
lead to protein misfolding diseases. The pharmacological chaperone-stabilized fold 
pathway is shown (green square); diflunisal, a small molecule being tested as a 
therapeutic for ATTR amyloidosis, has been shown to enhance this pathway. From 
Balch WE et al. Science. 319:916-919. (2008), reprinted with permission from AAAS. 
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protein that reportedly functions as an extracellular chaperone. The expression of 
CLU is increased in a wide variety of disease states and stresses, including cancer, 
atherosclerosis, myocardial infarction, scrapte, glomerulonephritis, and others 
(Rosenberg and Silkensen, 1995). Increased levels of CLU have been observed in AD 
where the chaperone has been found complexed to soluble amyloid protein, A~, and as a 
component of the amyloid plaques. In addition, CLU has been linked to cardiovascular 
diseases; it is a constituent of human atherosclerotic plaques, upregulated at mRNA and 
protein levels in myocarditis models, and localized to damaged myocardium in 
myocardial infarction (Rosenberg and Silkensen, 1995; Swertfeger eta!., 1996).CLU has 
a remarkable conformational adaptability that is typical of molecular chaperones; this 
structural flexibility is attributed to three large molten globule domains, three 
amphipathic regions, and two coiled-coil a.-helices (Figure 8). Moreover, this molecular 
structure of CLU is responsible for the unique high affinity, low specificity, binding 
property of the protein (Bailey eta!., 2001; Humphreys et a!., 1999; Nuutinen et a!., 
2009). CLU has been identified in cerebrospinal and seminal fluids, breast milk, urine, 
and plasma; gene expression occurs in testis, liver, stomach, brain, kidney, and heart 
(Aronow et al., 1993; Rosenberg and Silkensen, 1995). 
Studies suggest that the gene regulation of CLU is directly linked to the heat 
shock response through HSF1-HSF2 heterocomplex binding to a heat shock regulatory 
element in the CLU gene promoter. Thus, modulation of CLU gene transcription occurs 
in stress- or disease-induced states (Loison et a!., 2006). CLU is encoded by a single 
gene that is transcribed, alternatively spliced, and translated into at least three closely 
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Figure 8. Structural model of secreted clusterin. 
Secreted CLU is 427 amino acids in length and 75-80 kDa in size by SDS-PAGE 
analysis. The ~-chain includes N-terminal amino acids 1-205 (36-39 kDa) and the a-
chain is comprised of residues 206-427 (34-36 kDa). Shown are predicted secondary 
structures including three amphipathic a-helices (yellow ovals), two coiled-coil a-helices 
(blue rectangles), and five disulfide bonds linking the subunits (green blocks with black 
squares). Reprinted from Wilson MR, Easterbrook-Smith SB. Trends Biochem. Sci. 
25:95-98. Copyright (2000), with permission from Elsevier. 
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related protein isoforms, each with distinct subcellular and extracellular 
localization: secretory CLU (sCLU), Mr 75-80000; cytoplasmic CLU (cCLU), Mr 60-
64000; and nuclear CLU (nCLU), Mr 50000 (Caccamo et al., 2005; 2004; 2003; Moretti 
et al., 2007; Pucci et al., 2004; Scaltriti et al., 2004; Trougakos et al. , 2005; Yang et al., 
2000; Zhang et al., 2006). Secretory CLU is a pro-cell survival protein that is targeted to 
the endoplasmic reticulum (ER) by a leader peptide and internally cleaved from the 
unglycosylated cCLU to form the disulfide linked a-~ heterodimer. Dimeric sCLU 
subsequently undergoes extensive glycosylation in the Golgi prior to secretion (Figure 
8). N-linked glycosylation of sCLU constitutes as much as 17-27% by weight of the total 
mass of the 75-80 kDa protein and is heterogeneous in nature containing up to 7 different 
possible types of oligosaccharide structures (Kapron et al., 1997). A total of 6 N-linked 
glycosylation sites have been identified; 3 on the a-subunit (Mr 34-36000) containing 0-
30% carbohydrate at a64N, a81N, and a 123N, and 3 on the ~-subunit (Mr 36-39000) 
containing 27-30% carbohydrate at ~64N, ~ 127N, and ~ 147N (Kapron et al., 1997).The pro-
survival function of sCLU is attributed in part to its chaperoning action in the 
extracellular milieu. It has been demonstrated that sCLU can inhibit stress-induced 
protein aggregation by ATP-independent binding to hydrophobic regions of misfolded 
proteins thereby forming soluble, high molecular weight complexes (Narayan et al. , 
2011; Wilson et al., 2008). Sequence alignment analysis of sCLU with the well-defmed 
intracellular small heat shock protein, aB-crystallin, has revealed 25% homology 
between residues 57-107 of aB-crystallin and residues 286-343 of sCLU (Wilson and 
Easterbrook-Smith, 2000). Interestingly, this region of aB-crystallin is part of the 
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chaperone-active site and correlates with the predicted coiled-coil a-helix sequence in the 
~ chain of sCLU (Wilson and Easterbrook-Smith, 2000). Comparable long-lived 
complexes of sCLU and aS-crystallin with A~ (1-40) oligomers have been observed. 
These data demonstrate that an extracellular and an intracellular chaperone function 
similarly in preventing A~ (1-40) oligomerization and amyloid fibril formation (Narayan 
et al., 2012). 
Serum CLU is also a ligand for the cell surface receptor, megalin (LRP2); it has 
been shown to mediate clearance of A~ via receptor-mediated endocytosis and lysosomal 
degradation (Hammad et al., 1997). Interactions of sCLU with other LDL receptor 
family members has been observed and this mechanism may be involved in clearance of 
cellular debris by fibroblasts and epithelial cells (Wilson et al., 2008).Many other ligands 
of sCLU have been identified including apoA-1, glutathione-S-transferase, lipids, A~, 
complement components, heparin, immunoglobulins, GP330/megalin, prion peptide, 
TGF-~ receptor, and others (Ghiso et al., 1993; Hammad et al., 1997; Hochgrebe et al., 
1999; Humphreys et al., 1999; Jenne et al., 1991; Kounnas et al., 1995; McHattie and 
Edington, 1999; Pankhurst et al., 1998; Reddy et al., 1996; Tschopp et al., 1993; Wilson 
and Easterbrook-Smith, 1992). This diversity of ligands may suggest that sCLU has a 
wide range of functions. Further, the emergence of biochemical evidence indicating that 
sCLU can function as a chaperone supports the idea that this ubiquitous, extracellular 
protein may play a role in correcting misfolded plasma proteins, maintaining extracellular 
proteostasis, and facilitating the removal of misfolded proteins from circulation (Bjork 
and Sistonen, 2006; Carver et al., 2003; Humphreys et al., 1999; Lakins et al., 2001; 
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Poon et al., 2000; 2002; Stewart et al., 2007; Trougakos and Gonos, 2006; Wilson and 
Easterbrook-Smith, 2000; Wyatt and Wilson, 2010; Wyatt et al., 2011; 2009; Yerbury et 
al., 2007). 
Clusterin has been identified in several types of amyloid deposits including A~ 
plaques from patients with AD. In vitro studies characterizing the interactions of sCLU 
and prefibrillar amyloid structures have led to a model linking the extracellular chaperone 
to amyloidosis. It is proposed that sCLU acting as a molecular chaperone attenuates pre-
amyloid oligomer toxicity, and facilitates solubilization and clearance of amyloidogenic 
precursors from circulation. There is also additional in vitro evidence that at exceedingly 
low molar ratios of sCLU:amyloidogenic precursors, sCLU may actually enhance fibril 
formation (Yerbury et al., 2007). 
1.7 Clusterin Single Nucleotide Polymorphisms and Disease 
Recently, two independent genome-wide association studies (GW AS) identified 
an association of the CLU gene (CLU) intronic CIT single nucleotide polymorphism 
(SNP), rslll36000 (intron 8), with late onset AD (Harold et al., 2009; Lambert et al., 
2009). In addition, these studies also showed a correlation of CLU rs11136000 and the 
known AD risk variant, APOE c:4 (Lambert et al., 2009). Three additional studies of 
independent cohorts confirmed the CLU-AD association (Carrasquillo et al., 2010; 
Mengel-From et al., 2011; Seshadri et al., 2010). Moreover, Lambert et al. reported that 
two additional CLU SNPs, rs2279590 and rs9331888, were significantly associated with 
late onset AD using conservative statistical analyses. These SNPs were shown to be in 
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linkage disequilibrium, a non-random association among multiple alleles at separate loci 
that occurs at a higher frequency than expected by chance. In the study by Mengel-From 
et al., a significant association between the CLU rs11136000 T allele and better 
performance on a cognitive composition test was observed. These data corresponded to 
the minor allele (38%) that was initially found to be more frequent in controls than AD 
cases. Furthermore, this CLU SNP was shown to be associated with differing 
concentrations of plasma CLU, i.e. an allele-dose effect was observed in which the 
proposed AD-risk variant (C allele) was correlated with lower plasma CLU levels 
(Schfumann Bet al., 2011). It is not known how the CLU variant allele and AD risk are 
connected, but the ability of clusterin to function in protective mechanisms may play a 
role. 
The molecular analyses of CLU in AD are not the only investigations linking 
CLU genotype status to a protein misfolding disease. In 2008, a study of CLU variant 
status was carried out in patients with pseudoexfoliation (PEX) syndrome, an age-
dependent protein deposition disease where abnormal fibrillar material is deposited in 
both ocular and non-ocular tissues (Burdon KP et al., 2008). PEX syndrome pathology 
will be discussed in the section that follows. Burdon et al. studied the occurrence of 
SNPs in CLU based on linkage disequilibrium (LD) patterns in Caucasian samples 
genotyped as part of the International HapMap Project (de Bakker et al., 2005; 
The_International_HapMap_Consortium, 2003). The SNPs spanned the entire CLU gene 
and included rs11136000, rs2279590, and rs9331888. Nominally significant CLU SNP 
and haplotype associations with PEX syndrome were demonstrated, but the authors 
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concluded that there was no obvious consistency between haplotype and single SNP 
analyses (Burdon KP eta!., 2008). In 2009, a study exploring functional candidate genes 
associated with PEX reported that CLU SNP rs227950 and a five SNP CLU haplotype 
had a nominally significant association with the disease (Krumbiegel eta/., 2009). 
1.8 Pseudoexfoliation Syndrome 
PEX syndrome is a common, age-related systemic disorder defmed by the 
pathologic accumulation of abnormal extracellular fibrillar material in both intra- and 
extra-ocular tissues (Schlotzer-Schrehardt, 2009). The disease affects approximately 10-
20% of the population over the age of 60 years and is the most frequent cause of open-
angle glaucoma, accounting for 25% of all cases worldwide (Ritch, 1994). Despite being 
a systemic disease, PEX features fibrillar deposits that are primarily located on ocular 
structures of the anterior segment of the eye, lining surfaces bathed by the aqueous humor 
(Ritch and Schlotzer-Schrehardt, 2001). The current understanding of PEX molecular 
pathology characterizes the syndrome as a type of stress-induced elastosis in which 
excessive production and abnormal aggregation of elastic fiber components lead to the 
formation of fibrils. PEX fibrils, composed of laterally aggregated microfibrils with 
diameters measuring 8-10 nm, feature a complex cross-linked glycoproteinlproteoglycan 
structure in which numerous components have been identified (Schlotzer-Schrehardt, 
2009). Immunohistochemical and liquid chromatography tandem mass spectrometric 
analyses of PEX fibrils have demonstrated the presence of elastin, tropoelastin, amyloid 
P, vitronectin, fibronectin, heparin sulfate pro teo glycan, fibrillin-1, microfibril-associated 
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glycoprotein (MAGP-1), emilin, latent TGF-~ binding proteins (LTBP-1 and LTBP-2), 
complement components, cross-linking enzymes like lysyl oxidase-like 1 (LOXL 1 ), 
metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), and clusterin (Ovodenko 
et al., 2007; Ritch and Schlotzer-Schrehardt, 2001). Fibrillin-1, a large glycoprotein, is 
the main component of elastic microfibrils and presumably of PEX fibrils (Schlotzer-
Schrehardt, 2009). 
The presence of such a diverse collection of components in PEX fibrils has led to 
mechanistic models of syndrome pathogenesis that include excessive production and 
aggregation of elastic microfibril components, cross-linking processes, proteolytic 
imbalances between MMPs and TIMPs (Schlotzer-Schrehardt et al., 2003), increased 
cellular stress response, significantly elevated levels of fibrogenic TGF-~1 (Schlotzer-
Schrehardt et al., 2001 ), and the aberrant nucleation, aggregation and precipitation of 
protein to form deposited PEX fibrils (Schlotzer-Schrehardt, 2009). Although not 
categorized as an amyloid disease, PEX syndrome has characteristics that are strikingly 
similar to systemic amyloidosis, i.e. PEX and systemic amyloidosis are both protein 
conformational misfolding and aggregation disorders (Janciauskiene and Krakau, 2001; 
Schlotzer-Schrehardt and Naumann, 2006). 
1.9 Pseudoexfoliation Syndrome and Clusterin 
In ocular tissues, CLU expression has been found in the cornea, lens, ciliary body, 
retina, and optic nerve; the major source is ciliary epithelial cells which secrete CLU into 
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the aqueous humor of the anterior segment of the eye (Krumbiegel et al., 2009; Zenkel et 
al., 2006). Clusterin is normally present in the aqueous humor at approximately 752.3 
ng/mL and at a concentration ratio to total protein similar to that found in serum (Dota et 
al., 1999). CLU has been implicated in numerous ocular pathophysiological processes 
including retinitis pigmentosa, retinal reperfusion injury, and light-induced photoreceptor 
cell degeneration; in each of these situations, there is pronounced upregulation of CLU in 
response to injury (Gwon et al., 2004; Jones et al., 1992; Wong P et al., 1994). 
Conversely, it is interesting to note that CLU expression levels of both mRNA and 
protein were reduced in ocular tissues and the aqueous humor of patients with PEX 
syndrome (Zenkel et al., 2006). 
Studies have shown that TGF -~ 1 is a regulator of CLU expression on a cell type-
specific basis; both increased and decreased levels of CLU in response to TGF -~ 1 have 
been demonstrated (Ovodenko et al., 2007; Zenkel et al., 2006). The fmding of 
significantly elevated TGF-~1 m the aqueous humor of PEX eyes has led some 
investigators to postulate that CLU deficiency may be due to down regulation of gene 
expression in these ocular tissues (Zenkel et al., 2006). Alternatively, it has been argued 
that low levels of CLU in the aqueous compartment and the presence of strong CLU 
immunoreactivity in PEX deposits may be a feature of late disease onset, i.e. slow but 
chronic CLU accumulation in the PEX deposits over years of disease progression despite 
local down regulation of synthesis (Ovodenko et al., 2007). 
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1.10 Dynamics and Plasticity of Amyloid Fibrils 
Amyloid fibrils are not the rigid, static, and inert proteinaceous deposits as was 
previously thought. Rather, the fibrils are extremely dynamic and closely influenced by 
the surrounding environment. The plasticity of amyloid fibrils can be attributed to a 
number of different phenomena that are only beginning to be identified. Examples of 
influential processes include biophysical changes in oligomer and fibrillar structures by 
conversion, fibril extension, and reversion; and complex biological processes which take 
place in the surrounding milieu and involve enzymatic activity with a capacity to alter the 
nature of surrounding tissues and deposited fibrils. 
The ultrastructural heterogeneity among fibrils of different protein compositions 
is evident, as described previously in section 1.2 (Chiti and Dobson, 2006; Wetzel eta!., 
2006). Wetzel eta!. highlighted both the polymorphic character and isomorphic nature 
of amyloid fibrils by showing that a polypeptide chain can form various aggregate 
morphologies (Figure 3) and demonstrating that polypeptides of different sequence and 
length take on similar fibrillar morphology. Studies have also validated the long held 
belief that structural reorganization of early state amorphous oligomers to more highly 
organized oligomers occurs during aggregation and progression to ~-sheet rich fibrils via 
a phenomenon known as nucleated conformational conversion and likely to be a 
determinant in oligomer toxicity (Campioni eta!., 2010; Carulla et al., 2010; Serio eta!., 
2000). Furthermore, a mechanism of molecular recycling of amyloid fibril components 
has been observed, whereby amyloid subunits continuously dissociate and associate to 
form fibrils (Carulla eta!., 2010; Sanchez et al., 2011). 
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Fibril modification has also been shown to be the result of enzymatic activity. 
Some of the first reports to describe enzyme associations with amyloid fibrils showed the 
presence and activity of human neutrophil elastase with ex vivo LC, amyloid A, and TTR 
amyloid fibrils purified from autopsied tissues (Skinner et al., 1983; Skinner et al., 1986). 
It was again recently demonstrated that neutrophil elastase has the capacity to fragment 
amyloid fibrils derived from a-synuclein, Sup35, and TTR proteins (Azevedo et al., 
2012). The elastase is part of neutrophil extracellular traps (NETs), which are DNA traps 
decorated with proteins such as elastase and histones that are released by neutrophils in 
response to pathogens. Azevedo et al. discovered that neutrophils release NETs in 
response to amyloid fibrils and showed that newly fragmented TTR amyloid is cytotoxic 
to both BHK-21 kidney-derived fibroblasts and Hep-G2 human hepatocyte cell lines. 
These fibrillar fragments were reactive to the All anti-amyloid oligomer polyclonal 
antibody which has been shown to have conformation-dependent reactivity for soluble 
amyloid aggregates regardless of protein sequence (Kayed et al., 2003). In addition, 
NETs were found to be colocalized with thioflavin-S stained amyloid deposits in post-
mortem lung and skin from patients with AL amyloidosis. These tissues showed the 
presence of All reactive oligomers present and adjacent to the NET markers. 
Matrix metalloproteinase (MMPs) have been shown to digest amyloid fibrils 
derived from different protein precursors including Af3 (Backstrom et al., 1996; Liao and 
Van Nostrand, 2010; Yan et al., 2006), and TTR (Sousa et al., 2004). Evidence for 
proteolytic cleavage of LC amyloid post-deposition by MMPs has also been reported 
(Enqvist et al., 2009). The dysregulation ofMMPs and TIMPS is known to be associated 
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with AD (Backstrom et al., 1996), the systemic amyloidoses (Biolo et al., 2008; Sousa et 
al., 2004), and pseudoexfoliation (PEX) syndrome (Ronkko et al., 2007; Schlotzer-
Schrehardt et al. , 2003). Specifically, the gelatinases, MMP-9 and MMP-2 may play a 
role in amyloid fibril formation and/or homeostasis. 
1.11 Amyloidosis and Clusterin 
The association of sCLU with the systemic amyloid diseases may be the result of 
tissue specific pathophysiological processes triggered by the extracellular deposition of 
amyloid fibrils . Localized tissue responses involving dynamic structural changes in both 
extracellular matrix components and fibrillar protein deposits may be a common feature 
of the amyloid disease mechanism. One such process common among the amyloid 
diseases is the proteolytic imbalance between matrix metalloproteinase (MMPs) and their 
inhibitors (TIMPs). Interestingly, amyloid deposits of A~, TTR, and LC, and the 
abnormal intraocular PEX material deposited extracellularly in PEX syndrome, all show 
significant associations with sCLU (Creasey et al., 201 0; Greene et al., 2011; Nuutinen et 
al., 2009; Ovodenko et al., 2007). In addition, a decrease of sCLU protein and mRNA in 
the aqueous humor and anterior segments of glaucomatous eyes afflicted with PEX 
syndrome has been observed (Zenkel et al. , 2006). One possible explanation for these 
related observations between seemingly unrelated pathologies may be at the level of a 
tissue-specific response to extracellular proteinaceous deposits. 
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1.12 Specific Aims 
The objective of this research is to investigate the potential role of the 
extracellular molecular chaperone, CLU, in systemic amyloid disease. We hypothesize 
that CLU is part of a proteostatic mechanism to remove amyloidogenic precursor proteins 
from circulation by complexing with these precursors and preventing proteotoxic 
stresses; however, in systemic amyloidosis, there is dysregulation of the proteostasis 
network. Moreover, we postulate that a localized tissue response consisting of robust 
proteolytic activity can lead to cleavage of amyloid fibrils and binding of sCLU from the 
extracellular milieu as newly exposed hydrophobic regions on the amyloid protein are 
exposed. 
The present study focuses on providing histologic evidence, and molecular and 
biochemical proof of associations between human CLU and amyloidogenic TTR 
proteins. Our investigative emphasis is on transthyretin-based senile systemic 
amyloidosis (SSA) and amyloidotic cardiomyopathy, and includes exploration of possible 
diagnostic or therapeutic implications of CLU biology. Additionally, elucidating the 
possible role ofCLU in TTR amyloid aggregation through the biochemical study of wild-
type and variant forms TTR is a central goal to this research. To this end, the specific 
atms are: 
Aim 1. To characterize the association of clusterin with systemic amyloid disease. 
a. Analyze amyloidotic tissues for the presence of CLU in samples from patients with 
and without cardiomyopathy and renal involvement. 
b. Examine amyloid fibrils purified from patient tissues and co-purified components. 
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c. Investigate serologic differences of CLU in amyloid patient specimens. 
d. Genotype correlation analysis of disease associated clusterin gene SNPs with amyloid 
patient serum CLU levels. 
Aim 2. To study the biochemical and pathological nature of molecular interactions 
between clusterin and TTR. 
a. Determine the amyloidogenic potential of wild-type TTR in the presence and absence 
ofCLU. 
b. Provide direct biophysical evidence for in vitro associations ofTTR and CLU. 
c. Test the interactions of CLU and variant TTR proteins with decreased tetramer 
stability. 
d. Demonstrate functional influences of CLU on altering the amyloidogenic nature of 
wild-type and TTR variants. 
1.13 Significance 
Investigation into the role of sCLU in amyloidosis may help to elucidate a natural 
proteostatic mechanism which exists to prevent TTR amyloid aggregation. In addition, 
these studies may reveal an aberrant or dysfunctional aspect of sCLU that is present in 
patients with systemic TTR amyloidosis. Evaluation of CLU as a disease-modifying 
gene by SNP and haplotype analyses in the systemic amyloidoses may provide a genetic 
indicator for risk of amyloidosis, organ system involvement, or survival. In addition, this 
evaluation may strengthen the notion that the chaperoning function of CLU contributes to 
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the pathogenic mechanism of amyloidosis. The possible effect of CLU genotype or 
haplotype on plasma CLU levels may also contribute to possible changes in circulating 
CLU levels of patients with amyloidosis. Lastly, certain aspects of CLU biology, 
genetics, and biochemistry could have the potential to be exploited for diagnostic or 
therapeutic strategies in the systemic amyloidoses. 
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Chapter 2. Methods 
2.1 Study Cohorts 
Patient information and biological samples were obtained from the Boston 
University Amyloidosis Center repository with the approval of the Institutional Review 
Board at the Boston University Medical Campus in accordance with the Declaration of 
Helsinki. Clinical data included details of history, physical examination, and routine 
laboratory studies. The diagnosis of amyloidosis was based on histological proof of 
Congophillic fibrillar deposits in fat aspirates or tissue biopsies. Amyloid disease type 
was determined by a combination of immunochemical, biochemical, and genetic 
techniques. AL amyloidosis was established by the presence of a plasma cell dyscrasia 
identified by clonal plasma cells in a bone marrow biopsy and evidence of a monoclonal 
immunoglobulin LC by serum and urine immunofixation electrophoresis and/or free light 
chain nephelometry. Identification of a pathologic TTR gene mutation and/or mutant 
protein indicated ATTR amyloidosis. In SSA, the diagnosis was made when testing for 
ALand ATTR were negative and there was immunological or biochemical proof of wild-
type TTR in the amyloid deposits. Cardiac function was assessed by echocardiogram. 
Left ventricular mass (L VM) was derived from the formula described by Devereux et al. 
(Devereux RB et al., 1986). Patients were identified as having cardiac involvement if 
they had clinical symptoms of congestive heart failure (defined as New York Heart 
Association Functional Class > 1) and/or septal or ventricular wall thickening > 12 mm 
on echocardiogram without a history of hypertension. Electrocardiogram (ECG) and 
brain natriuretic peptide (BNP) were also determined. 
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2.2 Antibodies, Human Control Sera, and Other Reagents 
Polyclonal rabbit anti-human CLU (H-330), monoclonal mouse anti-human CLU 
(CLI-9), and goat anti-rabbit lgG-horseradish peroxidase (HRP) mouse/human adsorbed 
antibody solutions were purchased from Santa Cruz Biotechnology (Santa Cruz, CA); 
polyclonal rabbit anti-human-prealbumin (TTR) from DakoCytomation (Glostrup, 
Denmark) and polyclonal goat anti-human-kappa LC conjugated to HRP from Novus 
(Littleton, CO) were also obtained. Monoclonal mouse anti-human CLU (G7) lgG 1 was 
purified from a mouse hybridoma cell line described below. IgG 1Envision+ System-HRP 
labeled polymer anti-rabbit secondary antibody, proteinase K, Dako antibody diluent, and 
TBST were from DakoCytomation (Glostrup, Denmark). 
For the ELISA measurements of serum CLU levels, commercial control sera 
collected from healthy, consented, paid human donors from FDA-licensed and inspected 
donor centers, was purchased from Bioreclamation, Inc. (Westbury, NY). In addition, 
sera from patients with ischemic and non-ischemic CMP, left ventricular ejection fraction 
(L VEF) < 40%, and no amyloid disease were obtained from Dr. Flora Sam, Whitaker 
Cardiovascular Institute, Boston University School of Medicine. 
Congo red, hematoxylin, citra plus®, and Power Block® solutions used for 
histopathology and electron microscopy were purchased from BioGenex (San Ramon, 
CA). Polyclonal goat anti-rabbit lgG:lOnm antibody solution (British BioCell 
International, Cardiff, UK), Lowicryl® K4M resin, and formvar film 150 square mesh 
nickel grids were all acquired through Electron Microscopy Sciences (Hatfield, PA). 
Pierce ECL Plus Western blotting substrate used for immunoblot development was 
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obtained through Thermo Scientific (Rockford, IL). All other chemicals were from 
Fisher (Fairlawn, NJ) or Sigma (St. Louis, MO) and were of the highest grade available. 
2.3 Tissue Congo Red Staining and Immunohistochemistry 
Formalin-fixed, paraffin-embedded cardiac tissues were serially sectioned to 5 
)liD thickness and processed for Congo red staining and immunohistochemical analysis. 
For Congo red staining, deparaffmized sections were counterstained with Mayer's 
hematoxylin for 1 min, placed in alkaline 80% alcohol/NaCl for 20 min, stained in 
alkaline Congo red for 20 min, rinsed in ethanol and xylene, and observed by polarized 
light microscopy. 
Indirect immunohistochemical techniques with rabbit anti-human pnmary 
antibodies and goat anti-rabbit secondary antibodies conjugated to HRP were used for 
analyses of CLU and TTR in tissue sections. A direct method, performed with anti-
human free kappa LC antibodies conjugated to HRP, was used for kappa LC evaluation. 
For studies of CLU and LC, slides were initially boiled in antigen retrieval citra plus® 
solution and cooled for 20 min to room temperature; in TTR analyses, slides were pre-
treated in 6 M guanidine, pH 7.4 for 1 h. Subsequently, all slides were washed with 
dH20 and rinsed using TBST wash buffer. Tissue sections were applied to slides, 
blocked with fresh Power Block® and rinsed with TBST wash buffer using the Dako 
Autostainer Plus® automated system from DakoCytomation (Glostrup, Denmark). Using 
Dako diluent buffer, stock antibody solutions were diluted 1:50 for CLU H-330, 1:1000 
for TTR, and 1:100 for kappa LC-HRP antibodies; sections were incubated in 200 )lL of 
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appropriate primary antibody dilutions for 30 min. For the TTR studies, sections were 
treated with proteinase K prior to incubation in primary antibody. For analyses of CLU 
and TTR, 200 J.!L of Envision+ System-HRP labeled polymer anti-rabbit IgG secondary 
antibody was applied for 30 min, washed with TBST, and treated with diaminobenzidine. 
Sections were counterstained with Harris' modified hematoxylin. Imaging was 
performed under bright field microscopy using a SPOT Insight camera with SPOT 
Advanced 4.6 software. 
2.4 Immunogold Labeling and Electron Microscopy 
Frozen tissues were cut to no greater than 1 mrn thickness and fixed overnight in 
4% paraformaldehyde at 4°C. Sections were washed in sodium cacodylate buffer 
(Electron Microscopy Sciences, Hatfield, PA) and dehydrated in 50, 75, and 90% 
dimethylformamide solutions. Tissues were embedded in fresh Lowicryl® resin and 
ultra-thin sections were placed on nickel grids. 
Tissue sections were blocked for 1 h with 1.0% bovine serum albumin (BSA), 
5.0% normal goat serum in 0.05 M tris, pH 7.4. Stock primary antibody solutions were 
diluted with 0.5% BSA, 0.1% fish gelatin, 0.05% Tween-20 in 0.05 M tris, pH 7.4 as 
follows: 1:5 for CLU H-330, 1:300 for TTR, and 1:4000 for kappa free LC antibodies. 
Samples were incubated with appropriate primary antibody dilutions overnight at 4°C, 
rinsed, and treated with a 1: 10 dilution of 10 nm gold particles conjugated to goat anti-
rabbit IgG for 1 h. Grids were negatively stained using 4% uranyl acetate and 0.4% lead 
citrate. Immunogold labeling was viewed at X80,000 magnification using Jeol Jem-1011 
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electron microscope (Peabody, MA) at 80 kV. Electron micrographs were acquired using 
a Gatan ES 1 OOOW Erlangshen CCD camera and Gatan digital micrograph software 
(Pleasanton, CA). 
2.5 Cardiac Tissue Whole Protein Extraction and Immunoblot Analyses 
Briefly, biospecimens were washed using cold 12 mM phosphates, 137 mM NaCl, 
2.7 mM KCl, pH 7.4, and nuclease free H20. Next, 7 M urea, 2 M thiourea, 65 mM 
dithiothreitol (DTT), and 4% CHAPS were added at 300 JlL I 100 mg of tissue. Samples 
were homogenized using the TissueRuptor (Qiagen, Venlo, Netherlands) and centrifuged 
for 1.5 hat 4°C and 25,000 ref. Supernatant protein concentrations were determined and 
samples stored at -80°C. Samples were dissolved in SDS-PAGE reducing sample buffer 
(Laemmli, 1970) (10 mM Tris, 1 mM EDTA, 2.5% (w/v) SDS, 5% (v/v) 2-
mercaptoethano1, 0.001% (w/v) bromophenol blue, pH 8.0) and equal amounts of total 
protein were loaded per well for each blot as follows: CLU, 40 Jlg; TTR, 2 Jlg; kappa 
LC, 1 Jlg. Extracts were electrophoresed using 8-16% gradient tris-HCl, SDS-gels and 
following transfer, membranes were probed using the Snap i.d. system (Millipore, 
Billerica, MA) with H330 polyclonal anti-CLU IgG, goat anti-rabbit IgG conjugated to 
HRP, and developed using ECL Plus. 
2.6 Cardiac Tissue Amyloid Fibril Isolation and Analysis 
The water extraction method for amyloid fibril isolation was used to separate 
amyloid fibrils from blood, cellular, and extracellular matrix components of autopsied 
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Figure 9. Water extraction method for isolating cardiac tissue deposited amyloid 
fibrils. 
The fractions most enriched in amyloid fibril material are the water wash and top layer 
samples (Skinner M, 1982). Each fraction was dialyzed into water and lyophilized 
separately. 
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Tissue Deposited Amyloid Fibril Extraction Procedure 
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cardiac tissues (Skinner M, 1982). This procedure is outlined briefly in Figure 9. Forty 
milligrams of lyophilized material was solubilized in 5 mL of PBS, 6 M guanidine HCl, 
and 4 mg/mL DTT at 37°C with end-over-end rocking for 72 h. Solutions were 
centrifuged at 1500 x g for 10 min; 3 mL of supernatant was dialyzed against PBS for 48 
h with one buffer exchange. Preparation of samples for quantification and SDS-PAGE 
analysis was accomplished by adding 1.68 g of urea, 610 mg thiourea, 40 mg DTT, and 
200 mg SDS to the dialyzed fractions; the fmal volume was adjusted to 4 mL yielding a 
solution of 7 M urea, 2 M thiourea, 65 mM DTT, and 2% SDS. The protein 
concentration of each fraction was determined using the 2-D quant kit (GE Healthcare, 
Piscataway, NJ). Samples were mixed in Laemmeli SDS-PAGE load buffer and 20 J.lg of 
total protein was loaded onto a 12% SDS polyacrylamide gel. Following electrophoresis, 
samples were transferred to membranes which were incubated in 10 mL 5% dry non-fat 
milk-TBST blocking buffer (150 mM NaCl, 10 mM tris, 0.05% (v/v) Tween-20, pH 8.0) 
for 1 h. Membranes were rinsed for 5 min in TBST three times and incubated in 10 mL 
of 2.5% dry non-fat milk-TBST for 2 h containing a 1:2000 dilution of H330 polyclonal 
anti-CLU IgG. Three 5 min rinses in TBST were followed by a 1 h incubation in 10 mL 
of 2.5% dry non-fat milk-TBST containing a 1:4000 dilution of goat anti-rabbit HRP 
IgG. Finally, membranes were rinsed again and developed using ECL Plus Western 
blotting substrate. 
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2. 7 Serum Clusterin Measurements by ELISA 
a. Indirect Capture ELISA 
High-binding 96-well microplates (R&D Systems, Minneapolis, MN) were coated 
overnight at 4°C with 100 f..LL of 62.5 ng/mL of mouse monoclonal anti-human CLU 
(CLI-9) capture antibody and blocked with Blocker® Casein in PBS solution (Thermo 
Scientific, Rockford, IL). Serum samples were diluted 1:40 in 0.1% BSA, 10% 
Blocker® Casein in PBS, 0.05% surfact-amp 20® (Thermo Scientific, Rockford, IL) in 
PBS, and 100 f..LL applied to microplates in triplicate. Samples were incubated for 2 h 
with rotation at 90 rpm. Standard curves were generated for independent microplates 
using recombinant CLU (rCLU) purchased from R&D Systems, Minneapolis, MN. 
Plates were washed and 100 f..LL of 2.5 f..Lg/mL rabbit polyclonal anti-human CLU (H330) 
primary detection antibody added to each well. Following 2 h of incubation, 100 f..LL of 
80 ng/mL preadsorbed goat anti-rabbit secondary detection antibody was added; plates 
were rotated for 2 h at 90 rpm. ELISA solutions were developed for 20 min using 100 
f..LL ofH20 2 and 3,3',5,5'-tetramethylbenzidine chromagen (R&D Systems, Minneapolis, 
MN); development was halted with 100 f..LL of 4 N sulfuric acid. Absorbance values were 
measured at 465 nm and 590 nm using a PowerWaveX spectrophotometer (BioTek, 
Winooski, VT). Standard curves and final serum concentrations were determined by a 4-
parameter logistic curve fit using KC4 software (BioTek, Winooski, VT). 
b. Direct Capture ELISA 
NUNC MaxiSorp® 96-well clear flat bottom ELISA plates were directly coated 
with 100 f.lL of either rCLU standards or patient serum samples diluted to 1:500 in PBST 
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diluent buffer (PBS, 0.2% surfact-amp 20®, pH 7.0). A 12-point standard curve 
spanning a concentration range from 32.000-0.016 f.!g/mL was used on each plate. 
Microplates were sealed and stored for 24 h at 4°C for sample binding. The following 
day a 1% BSA-PBS blocking buffer was warmed in a 37°C water bath for 30 min. The 
microwell plates were washed 3 times with 200 f.!Liwell PBST wash buffer (PBS, 0.1% 
surfact-amp 20®, pH 7.0). Warmed blocking buffer (200 f.!L) was added to each well. 
Plates were sealed, placed into a small cardboard box, and incubated in a 37°C warm air 
incubator for 1 h. The wash step described above was then repeated and primary 
detection CLI-9 mouse monoclonal anti-CLU IgG, diluted to 0.1 mg/L in PBST diluent 
buffer, was added (100 f.!Liwell). Sealed plates were again incubated at 37°C for 1 h, 
washed, and 100 f.!L of secondary detection goat anti-mouse HRP-conjugated lgG, 
diluted to 0.1 mg/L (1 :2000) in PBST diluent buffer was added to each well. Following 1 
hat 37°C, plates were washed and ELISA solutions were developed for 35 min using 100 
f.!L ofH20 2 and 3,3',5,5'-tetramethylbenzidine chromagen; development was halted with 
50 f.!L of 4 N sulfuric acid. Absorbance values were measured at 450 nm and 570 nm 
using a PowerWaveX spectrophotometer (BioTek, Winooski, VT). Standard curves and 
fmal serum concentrations were determined by a 5-parameter logistic curve fit using KC4 
software (BioTek, Winooski, VT). 
2.8 Clusterin ELISA Statistical Analysis 
Data from the ELISA measurements of serum CLU and echocardiography were 
analyzed using GraphPad Prism 5 software (La Jolla, CA). One way analysis of variance 
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and Tukey-Kramer multiple comparison post-ANOVA, and Pearson or Spearman 
correlation tests were conducted to determine significance. Continuous variables are 
described as mean ± standard error. Statistical significance was assigned by the criterion 
of P::; 0.05. 
2.9 Genomic DNA Isolation and CLUrs1113600 SNP Genotyping 
Patient genomic DNA (gDNA) was isolated from whole blood or serum using the 
QIAcube robotic system and QIAamp DNA Mini Kit (Qiagen, Venlo, Netherlands). 
Samples were quantified using the Quant-iT™ PicoGreen® double stranded DNA Kit 
and fluorescence detection using the Horiba Jorbin FluoroMax-4 Spectrofluorometer 
(Horiba Scientific, Irvine, CA). TaqMan® SNP Genotyping Assay (Life Technologies, 
Carlsbad, CA) was used to assess CLU rs11136000 genotypes. A wet gDNA delivery 
method was used for 96-well plate polymerase chain reaction (PCR) setup. Briefly, 
11.25 11L (16.9 ng) of gDNA sample in DNase free water was added to each well. A 
reaction mixture containing 12.5 11L of TaqMan Universal PCR Master Mix (2x) No 
AmpErase UNG, and 1.25 11L of 20x working rs11136000 SNP genotyping assay mix 
was added to each well. PCR amplification and fluorescence monitoring was carried out 
using the Bio-Rad ClOOO Thermal Cycler with CFX96 Real-Time System (Bio-Rad, 
Hercules, CA). The ramp rate was adjusted to 1.6°C/sec and the following amplification 
method was used: 40 cycles of 95°C for 10 min, 92°C for 15 min, 60°C for 1 min, and 
92°C for 15 min; a final step of 60°C for 1 min. Low gDNA concentrations from serum 
derived samples were amplified an additional 20 cycles to boost fluorescence. Endpoint 
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fluorescence readings were taken for each well usmg the VIC (excitation 488 run, 
emission 552 run) and FAM (excitation 488 run, emission 518 run) fluorophore settings. 
Data was normalized to no gDNA template controls (NTC) using Bio-Rad CFX Manager 
software. 
2.10 Expression and Purification of Recombinant Transthyretin 
Recombinant TTR (rTTR) was expressed and purified according to Kingsbury et 
al. (Kingsbury et al. , 2007). Modification of the expression vector for rTTR variant 
synthesis was carried out by site-directed mutagenesis using the QuikChange XL Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA). Specifically, sequences were 
modified for substitutions of valine to alanine at position 30 (V30A), valine to isoleucine 
at position 122 (V122I), and leucine to proline at position 55 (L55P) to generate 
tetrameric variants of rTTR. In addition, mutations for F87M and Lll OM were 
introduced to generate an engineered TTR subunit that does not form tetramers, referred 
to as monomeric rTTR (M-TTR, MonoTTR) (Jiang et al., 2001b). 
2.11 G7 Anti-human Clusterin Monoclonal Mouse IgG1 Purification 
a. Hybridoma Stock Acclimation and Expansion 
A mouse G7 hybridoma cell line producing monoclonal antibodies against human 
serum CLU was received as a generous gift from Professor Lucien A. Aarden of The 
University of Amsterdam, Netherlands. The G7 hybridoma cell stock was quickly 
thawed in a 37°C water bath and contents emptied into a 50 mL conical tube. Complete 
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IMDM media supplemented with 10% FBS, 8 mM L-glutamine, 1% penicillin, 1% 
streptomycin, and 50 J.!M of ~-mercaptoethanol was added drop wise to 10 mL and then 
filled to 40 mL. Cells were centrifuged at 1500 rpm for 10 min and the supernatant 
aspirated to remove DMSO containing freeze media. The cell pellet was resuspended in 
40 mL of complete media which had been warmed to 3 7°C and centrifuged. The cell 
pellet was then resuspended in 2 mL of 37°C complete media; T-25 culture flasks were 
inoculated with 8 mL media containing 0.625 x 106 cells/mL. Each flask was 
supplemented with recombinant mouse IL-6 (miL-6) (Life Technologies, Carlsbad, CA) 
to a final concentration of 50 ng/mL. Flasks containing cells were placed on a gentle 
orbital shaker inside a humidified 37°C culture incubator with 5% C02 . Hybridoma 
stocks were expanded to an approximate cell density of 1 x 106 cells/mL at about 3 days 
and passaged 1:4 into 75 mL culture flasks . 
Passaged cells were allowed to expand an additional 4 days, pooled, counted, and 
centrifuged for 10 min at 1500 rpm at 4°C. Supernatant conditioned media was 
withdrawn from the pellet and mixed 1:1 with fresh complete media. Freeze media was 
prepared by mixing the 1:1 fresh media and conditioned media with 7.5% DMSO. Cells 
from the pellet were resuspended in freeze media at a density of 5 x 106 cells/mL and 
aliquoted into 1 mL cryogenic vials. The vials were place inside an enclosed foam box 
with tape-sealed edges and frozen in a stepwise manner at -20°C for 1 h, -80°C for 24 h, 
and finally -150°C indefinitely. 
b. Hybridoma Adaptation to Serum-free Media 
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Hybridoma cells cultured for IgG1 purification were sequentially adapted to 
serum-free CD hybridoma media L-glut Neg. (Life Technologies, Carlsbad, CA) 
supplemented with 8 mM L-glutamine, 1% penicillin, 1% streptomycin, 50 f..i.M ~­
mercaptoethanol, and 50 ng/mL miL-6. In brief, hybridoma cells were quickly thawed in 
a 37°C water bath and inoculated at normal seeding cell density 0.625 x 106 cells/mL in a 
75:25 (v/v) mixture of serum supplemented:serum-free media. In three expansion steps, 
cells were incubated at 3 7°C with gentle orbital shaking until viable cell density reached 
1 x 106 cells/mL and passaged into 50:50 and 25:75 (v/v) mixtures of serum 
supplemented:serum-free media, and finally into 100% serum-free media. Hybridoma 
cultures for IgG1 containing supernatant purification were then expanded in serum-free 
media with decreasing concentrations of miL-6, i.e. 50% less miL-6 for each passage. 
Prior to further passaging, cells were grown to a density of 1-3 x 106 cells/mL. This 
process was carried out until a total of 1 L of hybridoma containing media was obtained. 
Cultures were allowed to grow to confluence for at least 1 week or until cells appeared 
non-viable. 
Hybridoma cell suspensions were harvested and pooled from all flasks. Culture 
flasks were rinsed with lgG binding buffer (3M NaCl, 1.5 M glycine, pH 8.9) and added 
to the hybridoma suspension pool. The suspension was divided into four 250 mL conical 
tubes and centrifuged in a fixed-angle rotor for 30 min at 4°C and 6000 rpm. IgG 1 
containing supernatants were then removed and frozen at -80°C until further clarification. 
c. Monoclonal IgG1 Purification 
Two frozen 250 mL aliquots of G7 hybridoma supernatant was rapidly thawed in 
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a 37°C water bath and held on ice. Twelve cOmplete, Mini, EDTA-free Protease 
Inhibitor Cocktail Tablets (Roche, Indianapolis, IN) were dissolved in 475 mL of IgG 
binding buffer and 25 mL of 0.5% sodium azide, and added to the supernatant. In a 
sterilized 1.5 L Erlenmeyer flask, 1 L of diluted hybridoma supernatant was mixed with 4 
mL of protein A/G Plus Agarose resin in a 50% slurry (Thermo Fisher, Rockford, IL) and 
stirred overnight at room temperature to bind monoclonal IgG1• Resin was allowed to 
settle for 1.5 h and approximately 800 mL of hybridoma supernatant removed. The 
remaining 200 mL was passed through a clean 15 mL Econo-Pac® 10DG 
chromatography column (Bio-Rad, Hercules, CA) to retain the resin. lgG1 bound protein 
AIG resin was allowed to settle and washed extensively using IgG binding buffer until 
the absorbance at 280 nm of the eluate was ::::; 0.001. lgG1 was eluted from the resin using 
0.1 M glycine, pH 3.0; 1 mL fractions were collected and monitored by absorbance 
measurements at 280 nm. Approximately 30 mL of eluate was pooled and dialyzed 
overnight at 4°C against PBS. G7-IgG1 in PBS was concentrated using Amicon Ultra-15 
centrifugal spin concentrators with a 10 K molecular weight cut off (Millipore, Billerica, 
MA) and quantified using a BCA protein assay (Thermo Fisher, Rockford, IL). 
2.12 Serum Clusterin Immunoaffinity Purification 
a. G7 Immunoaffinity Column Generation 
An immunoaffinity column was generated using covalent coupling of the G7 anti-
human CLU monoclonal IgG1 to cyanogen bromide (CNBr)-activated Sepharose® 4B 
resin (Sigma, St. Louis, MO). Stock G7-IgG1 was diluted to 7.5 mL at 4 mg/mL and 
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dialyzed overnight at 4°C against coupling buffer (0.1 M NaHC03, 0.5 M NaCl). To 
prepare a 5 mL G7-coupled Sepharose® resin bed, 1.43 g Sepharose® was placed in a 50 
mL conical tube and 20 mL of 1 mM HCl was added. The Sepharose® was allowed to 
swell for 15 min at room temperature with gentle end-over-end rocking. Meanwhile, 7.3 
mL of 4 mg/mL G?-IgG1 in coupling buffer was added to a 15 mL conical tube and pre-
coupling protein absorbance at 280 nm was recorded. The activated Sepharose® slurry 
was transferred to a 60 mL Pyrex No. 36060, ASTM 10-15M sintered glass funnel, 
washed thoroughly with 20 mL of coupling buffer, and immediately transferred to the 
tube containing the G7-IgG1. The coupling reaction was allowed to proceed at room 
temperature with gentle end-over-end rocking for 2 h; the mixture was subsequently 
centrifuged for 1 min at 2000 rpm and an absorbance measurement at 280 nm was 
recorded. Resin was washed 3 times with 10 mL of coupling buffer, blocked with 10 mL 
of 1 M ethanolamine-HCl, pH 9.0, and incubated at room temperature for 2 h with end-
over-end rocking. The G7-coupled Sepharose® slurry was transferred slowly to a clean 
glass chromatography column and washed with PBS until absorbance at 280 nm was~ 
0.01. At this point, 10-20 mL G7-coupled Sepharose® slurry was removed from the 
column, brought to final volume of 25 mL in PBS, and degassed for 2 h. The settled G7-
coupled Sepharose® was gently swirled by hand to create a suspension, collected and 
carefully pipetted down the side of a chromatography column so not to introduce air 
bubbles. The G7-coupled Sepharose® column was equilibrated with 5 column volumes 
of PBS-sodium azide for long term storage at 4°C. 
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b. Clusterin Purification from Human Serum 
The following column procedures were performed at 4°C in a walk-in cold room 
and all buffers were chilled overnight to 4°C prior to use. The G7 column was washed 
with 2 column volumes of PBS by gravity flow. A multi-channel peristaltic pump system 
using microcassettes and Masterflex tubing #6424-14 (Cole-Parmer, Vernon Hills, IL) 
was set to a flow rate of 0.5 mL/min (6 rpm). Pump system flow was set to deliver PBS 
through the in-flow tube to the top of the G7 column and fractions collected through the 
out-flow tube attached to the column base. The G7 column was allowed to equilibrate 
with PBS while serum was prepared. 
A sample (100 mL) of pooled human serum collected from healthy male 
individuals (Bioreclamation Inc., Westbury, NY) was quickly thawed at 37°C and diluted 
1: 1 into PBS containing 8 cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail 
Tablets (Roche, Indianapolis, IN), 5 mM EDTA. The diluted serum was chilled on ice 
for 10 min, filtered through multiple sterile 0.45 f.!m syringe tip filter discs, degassed on 
ice for 15 min, and then applied to the G7 column through the pump in-flow tube. A 
pump system flow rate of 0.5 mL/min (6 rpm) was maintained; the out-flow fractions 
were collected and saved for analysis of CLU depletion. The G7 column was washed 
extensively with PBS by gravity flow until absorbance at 280 nm of the eluate was :S 
0.01. Removal of ApoA-I bound to CLU was accomplished by washing the G7 column 
with 50 mL 0.5% Triton-X 100 in PBS and rinsing with 50 mL of PBS. Next, a pre-
elution washing step using 25 mL of 0.2 M sodium acetate, 0.5 M NaCl, pH 5.0 was 
performed for stringent purification of CLU. Serum CLU was eluted using 0.2 M 
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glycine, 0.5 M NaCl, pH 2.5 and monitored by absorbance measurements at 280 nm. 
Approximately thirty 1 mL elution fractions were collected and each was neutralized 
using 100 ~L of 1 M Na2HP04, pH 7.4. Purified serum CLU fractions were pooled and 
dialyzed against PBS overnight at 4°C, spin concentrated, and quantified. 
2.13 In Vitro Transthyretin Amyloid Fibril Formation Assays 
Under acidic conditions, wild-type and variant rTTR can be used to form in vitro 
amyloid via a multistage process that presumably involves tetramer dissociation, 
monomer unfolding, and fibril formation. It has been demonstrated that, at physiologic 
concentrations, wild-type TTR tetramer does not dissociate between pH 7.0 - 5.0 (Lai et 
al., 1996). The biochemical and biophysical techniques used to examine the influence of 
CLU on the various stages of TTR amyloid fibrillogenesis are described and diagramed 
in Figure 10. 
a. Citric Acid-mediated Transthyretin Aggregation 
A stock solution (4 mg/mL) of lyophilized rTTR, synthesized and purified as 
described previously, was prepared using picotech water. For the acid-mediated 
aggregation reaction, a 0.2 mg/mL (3.6 ~M) rTTR solution was prepared by diluting 25 
~L of the stock into 475 ~L of 100 mM KCl, 1 mM EDTA, 50 mM citric acid, and pH 
4.5. The sample was incubated at 37°C for 72- 120 h. 
b. Rapid Hydrochloric Acid-mediated Transthyretin Aggregation 
Wild-type rTTR (3.6 ~M) was dialyzed at 4°C against water for 24 hand then 10 
mM HCI, pH 2.0 for 96 h. Rapid aggregation and oligomer formation was induced by 
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Figure 10. Techniques useful in studying the stages of transthyretin amyloid fibril 
formation. 
Wild-type and variant TTR stability, oligomerization, and fibril formation were examined 
using CD, SPR, and ThT and CR binding as indicated. These methods were used for 
testing the influence of CLU on TTR at each of these stages. 
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addition ofNaCl adjusted to a concentration of 100 mM at 25°C (Lindgren eta!., 2005). 
Neutralization of the aggregation reaction was achieved using a 1:6 dilution of 0.5 M 
Na2HP04, pH 7.4. 
c. Mild Potassium Acetate-mediated Transthyretin Aggregation 
Other tetrameric forms ofTTR, including the wt and L55P variants were dialyzed 
against weak phosphate buffer (10 mM Na2HP04, 100 mM KCl, pH 7.4) overnight at 
4 °C. Monomeric rTTR was quickly buffer exchanged into weak phosphate buffer using 
Econo-Pac® lODG Columns (Bio-Rad, Hercules, CA) to prevent protein precipitation. 
TTR protein solutions were quantified and diluted to twice the desired reaction 
concentration (7.2 J.!M). Treatments of rTTR with diflunisal at 100M excess, or serum 
CLU or BSA at 7.2 J.lM (equimolar ratio to tetrameric TTR) were performed in weak 
phosphate buffer; mixtures were incubated for 2 h at room temperature. Next, rTTR 
fibril formation solutions with or without treatment were diluted 1: 1 into 200 mM 
potassium acetate, 100 mM potassium chloride, pH 5.0 and incubated at 37°C for up to 
10 days. 
2.14 Circular Dichroism Spectroscopy 
All CD spectra were collected using a Jasco J-815 spectropolarimeter equipped 
with thermoelectric temperature controllers (Jasco Inc., Japan). Far UV (193-250 nm, 1 
nm bandwidth) data was collected using a 1.0 mm path length quartz cell, smoothed 
using the Jasco noise reduction routine, normalized to protein concentration, and 
presented as molar ellipticity per residue units. CD melting and stability data were 
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recorded at 220 run to monitor ~-sheet structural changes while heating samples at 
2°C/min from 25 to 98°C. Melting temperatures (Tm) were determined from peak 
positions in the first derivative ofthe CD data (John and Weeks, 2000). 
2.15 Transthyretin Stabilization Assay 
Stock solutions (100 mM) of diflunisal and resveratrol, two small molecule TTR 
tetramer stabilizers, were prepared in water containing 1% EtOH, and 0.0075% DMSO. 
Recombinant TTR (7.2 !J.M) was pre-incubated for 2 hat room temperature with either 
diflunisal or resveratrol at 50-200 times molar excess. For analysis of tetramer stability 
after small molecule treatment, 1 M citric acid was used to adjust the pH of solutions to 
7.0, 5.2, 4.8, 4.4, 4.0, or 3.6. Aggregation reactions were performed at 37°C for 72 hand 
samples were cross-linked with 50% glutaraldehyde. Analysis of TTR solutions was 
accomplished using 10% SDS-PAGE with a 5% stacking gel; visualization of protein 
bands was achieved in 2 h using GelCode blue Coomassie blue G-250 reagent (Thermo 
Fisher, Rockford, IL). In addition, samples at pH 4.4 were incubated for 120 h at 37°C, 
centrifuged, and precipitates collected for Congo red binding analysis as described in the 
section which follows. 
2.16 Transthyretin Oligomer SDS-PAGE Analysis 
A hydrochloric acid-mediated rapid rTTR aggregation reaction was neutralized 
using a 1:6 dilution of 0.5 M Na2HP04, pH 7.4. Samples were either applied to a 
nitrocellulose membrane (described in the section which follows) or cross-linked for 2 
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min with 5 f.!L of 25% glutaraldehyde and the reaction quenched with 5 flL of 7% 
NaB~; 12.5 flL of 6x-SDS reducing Laemmli load buffer was added to each reaction 
solution and the mixture boiled for 5 min. Samples were analyzed for the presence of 
rTTR oligomers using 10% SDS-PAGE with a 5% stacking gel and developed for 2 h 
using GelCode blue Coomassie blue G-250 reagent (Thermo Fisher, Rockford, IL). 
2.17 All Anti-oligomer Dot Blot Assay 
Neutralized samples from the HCl acid-mediated aggregation assay were applied 
to a nitrocellulose membrane; the membrane was blocked for 1 h in 5% ECL Advance 
Blocking Reagent (GE Healthcare, Piscataway, NJ). A 1:3000 dilution of rabbit anti-
oligomer antibody, All (Life Technologies, Grand Island, NY), in 2.5% blocking reagent 
was applied to the membrane and allowed to stand overnight at 4 °C. Dot blotting of the 
membrane with secondary HRP conjugated goat anti-rabbit antibodies for 1 h was 
performed; development was achieved with ECL Plus. 
2.18 Surface Plasmon Resonance 
A ProteOn XPR36 Surface Plasmon Resonance (SPR) apparatus and sensor chips 
(Bio-Rad, Hercules CA) were used for this study. Tetramers and oligomers of rTTR, 
formed using the rapid HCl acid-mediated aggregation assay, were immobilized on a 
GLH high capacity sensor chip for studies of diflunisal and Congo red binding, and on a 
GLM medium capacity sensor chip for analysis of CLU binding. The rTTR ligands were 
immobilized using an amine coupling reaction; 2 f.!M rTTR ligand samples taken at 
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various time points from the aggregation assay were diluted in acetate buffer, pH 4.0 and 
injected into the SPR instrument for 5 min at a flow rate of 30 J..LLimin. A reference 
surface was always prepared in parallel using the same immobilization procedure in the 
absence of ligand. Final ligand immobilization levels achieved for GLH surfaces were as 
follows: native TTR tetramer = 11,000 resonance units (RU), 24 h TTR oligomers = 
5,100 RU, and 14 day fibrils = 5,400 RU. For GLM surfaces, the levels were: native 
TTR = 5,800 RU, 2 h TTR oligomers = 3,900 RU, 24 h oligomers = 4,000 RU, and 24 h 
oligomers (#2 replicate chip data)= 4,300 RU. In this system, 1 RU = 1 pg protein/mm2. 
Diflunisal, Congo red, and rCLU analytes were injected over immobilized rTTR ligands; 
diflunisal and Congo red samples were injected for 1-2 min at a flow rate of 100 J..LLimin, 
and rCLU for 5 min at a flow rate of 50 J..LLimin. PBS, 0.005% Tween-20 was used as 
running buffer and analyte diluent; 1% DMSO was added for diflunisal solubilization. 
Sensograms were double referenced to blank ligand surfaces and blank analyte buffer 
injections; data were modeled using the simple Langmuir 1:1 ( analyte:ligand) interaction 
model. 
2.19 Thioflavin T Binding Fluorescence 
Mild potassium acetate-mediated rTTR aggregation reactions were allowed to 
proceed for 72 hat 37°C; samples from the reactions were removed at various time points 
for analysis by thioflavin (Th) T binding fluorescence. In brief, 25 J..LL of rTTR 
aggregation reaction mixtures were diluted with 173 J..LL of 50 mM Tris, 100 mM KCl, 1 
mM EDTA, pH 8.0 containing 2 J..LL of ThT stock (1 mM) which was prepared with the 
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same buffer. A black 96-well microplate was loaded with triplicates of each sample at 
200 J.!Liwell and ThT fluorescence was measured (excitation 450 nm, emission 482 nm) 
using the Synergy H1 Hybrid Reader (BioTek, Winooski, VT). All data were normalized 
to triplicate blanks containing ThT. 
2.20 Congo Red Binding of Transthyretin Fibrils Formed In Vitro 
Insoluble amyloid fibrils from the mild potassium acetate-mediated assay were 
collected by centrifugation at 25,000 x g for 5 min and 300 J.!L of supernatant drawn off 
carefully so as not to disturb the pelleted material. The pellet was resuspended in 300 J.!L 
of 10 J.!M Congo red, 150 mM NaCl, 5 mM KH2P04, pH 7.4 to final volume of 500 J.!L. 
Spectrophotometric scanning in the wavelength (A.) range between 350-700 nm was 
performed on the samples using a Cary 300 UV-Vis Spectrophotometer (Agilent 
Technologies, Santa Clara, CA) to quantify Congo red binding to amyloid structures in 
suspension. A red shift of the spectrum in the wavelength range near 540 nm indicates 
the presence of amyloid (Klunk et al., 1999; Klunk et al., 1989). 
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Chapter 3. Histopathologic, Immunochemical, and Biochemical Evidence of 
Clusterin in Amyloid Deposits 
3.1 Demonstration of Clusterin in Cardiac Tissue Amyloid Deposits by 
Immunohistochemical Analysis 
Amyloid deposits were confirmed in autopsy specimens from SSA, ATTR, and 
AL cardiac tissues by histological staining with Congo red; cardiac tissue from a non-
amyloid heart transplant case served as a negative control. Light microscopic analysis of 
the stained SSA, ATTR, and AL tissues demonstrated the characteristic "apple green" 
birefringence of amyloid deposits when viewed under polarized light. 
The presence of CLU in cardiac amyloid deposits from patients with SSA, ATTR, 
orAL was initially investigated by immunohistochemistry (Figure 11). The biochemical 
nature of the amyloid deposits was confirmed in each case with the appropriate antibody 
treatment. TTR was identified in the SSA and ATTR samples (Figure llC and llD), 
and kappa LC was verified in the AL sample (Figure llE). The control sections were 
not immunoreactive to TTR or LC (Figure llA, B). Positive staining for CLU was 
observed in serial sections of all amyloid tissues tested (Figure llG-1), but not the 
control (Figure llF). Disruption of normal tissue architecture by the amyloid deposits, 
that were located adjacent to and surrounding cardiomyocytes, was evident. TTR and LC 
deposits exhibited pericellular staining patterns surrounding individual cardiomyocytes. 
The immunohistochemical results indicated that CLU was present and abundant in tissue 
sections that were positive for amyloid deposits; the pericellular staining pattern of the 
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Figure 11. Presence of clusterin in cardiac tissue containing amyloid deposits. 
The upper panel shows light microscopic results of immunohistochemical staining for 
amyloid precursor proteins, TTR (A, C, D) and LC (B, E), and CLU (F-I) in cardiac 
tissue specimens from a control (no-amyloid) and cases of SSA, ATTR, and AL 
amyloidosis. No staining was observed for TTR (A), LC (B), and CLU (F) in the control 
tissue. SSA and ATTR cardiac tissue sections showed extensive pericellular staining for 
TTR (C, D), as well as CLU (G, H); AL tissue sections showed extensive LC deposition 
(E) and strong CLU staining (I) compared to the control sections. hnages are x40. The 
lower panel (J) shows immunoblot analysis of protein extracts from cardiac amyloid 
cases and control tissue specimens. 
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amyloid proteins was also demonstrated for CLU and suggested that there might be an 
association of CLU with the amyloid fibrils in the deposit. Immunoblot analysis of total 
protein extracts from the cardiac tissue specimens confirmed the overabundance of the 
amyloid protein and presence of CLU in the SSA, ATTR, and AL samples compared to 
the control (Figure 11, lower panel). 
Serial sections of additional S SA, A TTR, and AL cardiac specimens were stained 
with Congo red, and analyzed by immunohistochemistry for TTR or LC, and CLU to 
confirm the previous results. Cardiac amyloid deposits were demonstrated by positive 
Congo red staining and green birefringence when viewed under standard and polarized 
light microscopy, respectively (Figure 12A-F). The apple green birefringence was 
readily observable by eye but difficult to acquire digitally without over staining. 
Subsequent serial sections exhibited positive staining of the deposits for TTR in SSA and 
ATTR (Figure 12G, H), LC in AL (Figure 12L) and CLU in all three amyloid tissues 
(Figure 12M-O). 
3.2 Confirmation of Clusterin in Amyloid Deposits by Electron Microscopic 
Studies 
To verify the presence of CLU in amyloid deposits composed of TTR or LC, 
immunogold staining and electron microscopic analysis of the SSA, ATTR, and AL 
tissue specimens were performed. Figure 13 shows examples of the results of these 
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Figure 12. Further immunohistochemical evidence of clusterin in cardiac amyloid 
tissue specimens. 
Cardiac tissues from additional SSA, ATTR, and AL autopsy cases were examined 
histochemically and immunohistochemically by light microscopy. Serial sections (5 ~m) 
from each case were used for staining with Congo red and immunohistochemical testing 
for TTR, LC, and CLU. Congo red treated sections containing amyloid deposits showed 
intense staining under standard light (A-C) and the characteristic apple-green 
birefringence was observed when viewed under polarized light (D-F). TTR was strongly 
present in the SSA (G) and ATTR (H) sections, while LC was only observed in the AL 
(L) tissue. CLU appeared to be highly abundant in the SSA, ATTR, and AL (M-0) 
samples. Images are x40. 
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Figure 13. Confirmation of clusterin in cardiac amyloid deposits by immunogold 
staining. 
Control (A, B), SSA (C, D), ATTR (E, F), and AL (G, H) cardiac tissue specimens were 
tested for the presence of TTR or LC (left column) and CLU (right column) using 
antibodies conjugated to 10 nm electron dense gold particles. The control tissue 
contained no amyloid deposits. Amyloid deposits (arrows) were observed in regions 
adjacent to cardiomyocytes and extensively gold labeled (arrowheads) with antibodies to 
TTR (C, E) or LC (G). Localization of gold particles corresponding to CLU was 
observed in cardiac amyloid deposits (D, F, H) from SSA, ATTR, and AL cases. Images 
are x80,000. 
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studies. Electron dense, 10 nrn gold particles corresponding to TTR- (Figure 13C, E), 
LC- (Figure 13G), or CLU- (Figure 13D, F, H) specific antibodies were visible in areas 
where fibrillar amyloid deposits were located, i.e. adjacent to the striated cardiomyocytes. 
Immunogold staining was negative in the control cardiac samples and in the amyloidosis 
patient samples where normal cellular and matrix components were visible; occasional, 
randomly occurring, gold particles observed in these regions were attributed to 
background staining. When control tissues were stained for CLU, the results were 
comparable to those observed in amyloid tissues treated with normal rabbit serum or PBS 
(Figure 14). These findings indicate that CLU is specifically associated with the amyloid 
fibrils in cardiac amyloid deposits occurring in patients with SSA, ATTR, or AL 
amyloidosis. 
3.3 Clusterin is Also Present in Renal Amyloid Deposits 
To determine if the association of CLU with TTR and LC amyloid deposits is 
unique to the myocardium, we investigated renal amyloid deposits composed of 'A LC 
(Figure 15). Sections from a kidney biopsy obtained on a patient with AL amyloidosis, 
previously shown to have extensive amyloid deposits by Congo red positive staining 
(data not shown), were used for this investigation. The thickened glomerular basement 
membranes and slightly distended mesangium within the glomeruli stained positive for A. 
LC by immunohistochemical treatment (Figure 15A, arrows). Identical structures in 
tissue serial sections showed strong positive staining for CLU (Figure 15B, arrows). 
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Figure 14. Negative controls for immunogold staining. 
Cardiac tissue sections from control (no amyloid deposits), SSA, A TTR, and AL 
amyloidosis cases were tested with primary immunobuffer (PIB) shown on the left (A, C, 
E, G) and normal rabbit serum (NRS) shown on the right (B, D, F, H). Arrows indicate 
amyloid deposits present in the tissues from SSA, ATTR, and AL (C-H). Extracellular 
matrix components (arrows) were observed in the control tissue (A, B). Images are 
x80,000. 
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Figure 15. Presence of clusterin in renal tissue containing amyloid deposits. 
Amyloid deposits containing CLU were not unique to cardiac tissues. Serial sections ( 5 
)liD) of a kidney tissue from an AL-A. LC autopsy sample were tested. 
Immunohistochemistry for LC (A) and CLU (B) demonstrated extensive staining for both 
proteins in the same regions of the tissue as indicated by arrows. Images are x40. 
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3.4 Identification of Clusterin in Ex Vivo Amyloid Fibrils 
For further proof that CLU was present in amyloid deposits and to help 
understand the nature of CLU-amyloid fibril interactions in cardiac tissues, we extracted 
amyloid fibrils from an ATTR autopsy heart specimen using the established method of 
Skinner et al. (Skinner et al., 1982) and analyzed all fractions (Figure 16). A basic 
outline of the procedure is discussed in the Methods section (Figure 9). An equal 
quantity of total protein from each fraction was analyzed by SDS-PAGE. Immunoblot 
analysis of cardiac amyloid-extracted fractions (Figure 16) showed co-purification of 
CLU in the fractions that were enriched with fibrils; an increased amount of CLU was 
observed in the water wash fractions (Figure 16, lanes 5 and 6). Relatively little CLU 
was present in the early saline and citrate washes (Figure 16, lanes 1-3) where other well 
defined amyloid components, like serum amyloid P-component, are dissociated from 
fibrils. 
3.5 Summary 
The analyses of tissues from patients with SSA, ATTR and AL systemic amyloid 
diseases demonstrated the abnormal presence and abundance of CLU in these pathologic 
specimens. Immunochemical techniques were used to establish the presence of CLU 
both in cardiac and renal amyloid deposits. Light microscopic examination of the TTR 
and LC cardiac amyloid tissues revealed a pattern of pericellular CLU staining 
comparable to that of the amyloidogenic protein. In the LC renal amyloid deposits, a 
similar overlap in staining of the amyloid protein and CLU was also noted. These results 
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Figure 16. Clusterin co-purifies with ex vivo amyloid fibrils. 
SDS-PAGE immunoblot analysis for CLU in fractionated material from ATTR cardiac 
tissue amyloid fibril extraction. For schematic outline of the multistep procedure used to 
generate amyloid fibrils see Figure 9. 
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were further clarified by electron microscopic analysis of the amyloid deposits 
demonstrating a specific co-localization ofCLU with TTR or LC cardiac fibrils. 
Biochemical studies of ex vivo fibrils further validated the microscopic results. 
Analysis of fractionated material, obtained at all steps in an extraction of amyloid fibrils 
from autopsied ATTR cardiac tissue, showed co-purification of CLU with the fibrils. 
Interestingly, amyloid fibril-associated components, like serum amyloid P-component 
know to bind to fibrils through ionic interactions, can be dissociated by treatment with 
citrate, a metal ion chelator. The interaction of CLU with amyloid fibrils appears to be 
non-ionic in nature based on the results from the fibril extraction. These results provide 
the first evidence of CLU association with amyloid fibrils in TTR and LC protein 
misfolding diseases. 
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Chapter 4. Serum Clusterin Concentrations in Systemic Amyloidosis 
4.1 Initial Quantification of Circulating Clusterin Levels by Indirect ELISA 
An indirect capture ELISA method was developed using monoclonal CLI-9 antibody for 
CLU capture and polyclonal H330 antibody for detection. Signal to noise ratios for 
varying capture and detection concentrations were used to guide in optimizing standard 
curve generation. CLU concentrations in SSA, ATTR, and AL sera were measured using 
the indirect ELISA method. The results were compared to levels in healthy controls and 
a cohort of ischemic and non-ischemic patients with CMP who did not have amyloidosis 
(Figure 17 A). The mean ages of the study and control groups were not significantly 
different. The mean ± SEM value of serum CLU measured for the healthy control group 
was 0.659 ± 0.085 mg/mL. CLU levels were significantly lower in SSA (0.174 ± 0.018 
mg/mL, P < 0.001). In the ATTR and AL groups, the concentrations were varied, and a 
sub-analysis of patients with and without CMP in these groups was performed. Serum 
CLU amounts in the ATTR and AL cohorts with no CMP were 0.743 ± 0.038 mg/mL and 
0.548 ± 0.062 mg/mL, respectively. Compared with age-matched healthy controls, the 
ATTR-CMP (0.386 ± 0.026 mg/mL) and AL-CMP (0.291 ± 0.055 mg/mL) groups were 
significantly lower (P < 0.001). Additionally, the ATTR-CMP and AL-CMP groups 
were significantly lower than either the ATTR no-CMP group or the AL no-CMP group 
(all P values were < 0.01). CLU levels were comparable in the ALand ATTR with no 
CMP groups, the non-amyloid patients with CMP, and the age- matched healthy controls. 
A comparison of groups with amyloidotic CMP (SSA, ATTR-CMP, AL-CMP) showed 
no significant difference. 
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Figure 17. Serum concentrations of clusterin in patients and healthy controls 
measured by indirect ELISA. 
(A) Serum levels of CLU were quantified by indirect ELISA in healthy, age-matched 
control subjects (white bar), patients with amyloidosis and no amyloidotic 
cardiomyopathy (AL and ATTR) or with cardiomyopathy unrelated to amyloidosis (gray 
bars), and patients with amyloidotic cardiomyopathy due to ATTR, AL, or SSA (black 
bars). ***P < 0.001; CMP = cardiomyopathy. (B) Retrospective analysis of brain 
natriuretic peptide (BNP) concentrations in matched serum samples where data were 
available. The 100 pg/mL threshold for clinical significance is indicated by a dashed 
line. Continuous variables are described as mean ± SE values. 
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When available, serum BNP levels in the tested samples were retrospectively 
analyzed to confirm the presence of heart failure in patients with CMP. BNP 
concentrations 2': 100 pg/mL were measured in all patients with amyloidotic CMP (SSA, 
ATTR-CMP, AL-CMP), as well as in patients with CMP unrelated to amyloidosis 
(Figure 17B). Mean BNP levels were highest in the AL-CMP group (1321 ± 468 
pg/mL); mean concentrations were comparable for ATTR-CMP (381 ± 78 pg/mL) and 
SSA (373 ±56 pg/mL). Median BNP values are also presented. In the patient groups 
with no CMP, BNP levels were within the normal range. Correlation analysis showed no 
significant association ofBNP with CLU (Spearman r = -0.2476, two-tailed P < 0.05, n = 
37). 
4.2 Revised Measurements of Serum Clusterin Concentrations by Direct ELISA 
To confirm the previous observations of lower serum CLU concentrations 
associated with cardiac amyloid disease status, a second ELISA was developed. 
Rigorous direct ELISA testing and serum sample analyses were conducted to ensure 
assay accuracy and reproducibility. Commercially obtained, healthy control serum 
samples, SPLl, SPL2 and SPL3 were randomly chosen to optimize sample dilutions and 
asses assay performance by dilution linearity testing (Table 1) and inter-assay variability 
testing (Table 2). Co-efficient of variation (CV), which shows the extent of 
measurement variability in relation to the mean, was calculated as a percentage using the 
following equation: CV% = (STDEV /MEAN)* 100. Dilution linearity testing across 5 
dilutions (1 :500 to 1 :2000) for SPL1, SPL2, and SPL3 resulted in CV values of 16.37, 
86 
Table 1. Dilution linearity of direct ELISA method. 
Commercial control sera, SPLl, SPL2 and SPL3, were used to analyze the direct ELISA 
dilution linearity performance. Coefficient of variation (CV) is expressed as a percentage 
and indicates measurement variability relative to the mean value. 
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SPLllnterassay Variability 
Dilution ELISA 1 ELISA 2 ELISA 3 Stdev Mean CV(%) 
500 391 .896 394.822 386.54 4.20 391.09 1.07 
750 441 .964 465.432 451 .771 11.79 453.06 2.60 
1000 509.887 521 .854 487.1 17.66 506.28 3.49 
1500 536.139 587.123 551 .981 26.09 558.41 4.67 
2000 620.535 616.163 554.477 36.94 597.06 6.19 
Dilution Linearity Across Plate Avgs 82.05 501.18 16.37 
SPL2 lnterassay Variability 
Dilution ELISA 1 ELISA 2 ELISA 3 Stdev Mean CV(%) 
500 207.932 216.959 195.923 10.55 206.94 5.10 
750 241 .906 226.719 215.445 13.28 228.02 5.82 
1000 231 .651 246.906 206.663 20.32 228.41 8.89 
1500 288.294 233.916 216.323 37.52 246.18 15.24 
2000 258.547 233.37 224.911 17.50 238.94 7.32 
Dilution Linearity Across Plate Avgs 14.83 229.70 6.46 
SPL3 lnterassay Variability 
Dilution EUSA1 EUSA2 EUSA3 Stdev Mean CV(%) 
500 236.769 203.766 179.361 28.811 206.632 13.94 
750 229.991 214.253 192.231 18.967 212.158 8.94 
1000 238.761 216.68 196.765 21.007 217.402 9.66 
1500 249.341 231 .223 197.734 26.182 226.099 11.58 
2000 268.034 232.872 209.88 29.288 236.929 12.36 
Dilution Linearity Across Plate Avgs 11.944 219.844 5.43 
.. 
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Table 2. Inter-assay variation of direct ELISA performance. 
Commercial control sera, SPLl, SPL2 and SPL3, were used to assess direct ELISA inter-
assay performance and reproducibility at a 1:500 sample dilution. Inter-assay variation 
testing was done in triplicate across 7 independent ELISA plates. Coefficient of variation 
(CV) is expressed as a percentage and indicates measurement variability relative to the 
mean value. 
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SPL11nterassay Variability: Serum CLU (~ml) 
lnterassay 
Replicate ELISA 1 ELISA 2 ELISA3 ELISA4 ELISA 5 ELISA& ELISA 7 Stdev Mean CV(") 
1 405.814 396.535 388.263 379.291 334.155 351 .637 360.64 25.88 373.76 6.92 
2 386.52 394.665 392.95 374.688 352.211 350.788 372.416 18.05 374.89 4.81 
3 383.355 393.266 378.408 374.688 345.261 355.046 375.04 16.54 372.15 4 .44 
Mean 391.90 394.82 386.54 376.22 343.88 352.49 369.37 19.61 373.60 5.25 
SPL2 lnterassay Variability: Serum CLU (~ml) 
lnterassay ELISA 1 ELISA 2 ELISA 3 ELISA4 ELISAS ELISA& ELISA 7 Stdev Mean CV(%) Replicate 
1 209.36 216.602 196.516 198.962 199.138 198.185 207.325 7.49 203.73 3.68 
2 209.718 218.387 196.962 191.427 204.358 200.203 209.725 9.07 204.40 4.44 
3 204.717 215.889 194.291 194.988 206.103 201 .55 21 1.694 8.03 204.18 3.93 
Mean 207.93 216.96 195.92 195.13 203.20 199.98 209.58 7.91 204.10 3.87 
SPL3 lnterassay Variability: Serum CLU (~ml) 
lnterassay ELISA 1 ELISA 2 ELISA 3 ELISA4 ELISAS ELISA& ELISA 7 Stdev Mean CV(%) Replicate 
1 242.937 211 .269 187.655 180.827 193.939 203.125 204.932 20.31 203.53 9.98 
2 236.262 203.861 180.637 179.656 194.978 207.184 210.381 19.49 201.85 9.66 
3 231 .107 196.169 169.792 185.523 196.363 209.22 211 .256 19.70 199.92 9.86 
Mean 236.77 203.77 179.36 182.00 195.09 206.51 208.86 19.32 201.77 9.57 
. 
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6.46 and 5.43%, respectively (Table 1). While testing results for SPL2 and SPL3 were 
quite acceptable, i.e. well below the 10% CV cut-off value, the data for SPL1 showed an 
upward trending in CLU concentration associated with increased dilution. These data 
may reflect the increased error introduced by dilution. This is more easily seen when 
looking at the inter-assay CV value data obtained in 3 separate ELISA tests where 
increasing CLU values paralleled increasing dilutions (Table 1). For all subsequent 
serum CLU measurements, 1:500 dilutions were used. Inter-assay variability testing of 
SPL1, SPL-2, and SPL-3 (performed on triplicate samples) resulted in acceptable assay 
performance across 7 separate ELISA tests, i.e. CV% values of 5.25, 3.87, and 9.57%, 
respectively (Table 2). 
The direct ELISA method was used to measure serum concentrations of CLU in 
the patient sera that had been quantified previously by indirect ELISA (Figure 18). Sera 
were tested twice, each time in triplicate, to assess inter-assay variability. The mean± 
SEM value of serum CLU measured for the healthy control group was 0.313 ± 0.029 
mg/mL (Figure 18A). CLU levels were significantly lower in SSA (0.065 ± 0.007 
mg/mL, P < 0.001). Serum CLU amounts in the ATTR and AL cohorts with no CMP 
were 0.224 ± 0.029 mg/mL and 0.239 ± 0.024 mg/mL respectively. Compared with age-
matched healthy controls, the ATTR-CMP (0.147 ± 0.016 mg/mL) and AL-CMP (0.145 
± 0.020 mg/mL) groups were significantly lower (P < 0.01). ATTR-no CMP and AL-no 
CMP groups did not significantly differ from either control groups or amyloid CMP 
groups. Expansion of sample number for the SSA cohort resulted in a 3-fold increase in 
the mean CLU concentration for the group (0.065 ± 0.007 mg/mL, n = 35; 0.187 ± 0.013 
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Figure 18. Revised serum concentrations in patients and healthy controls measured 
by direct ELISA. 
Serum levels of CLU were requantified by direct ELISA in healthy, age-matched control 
subjects (white bar), patients with amyloidosis and no amyloidotic cardiomyopathy (AL 
and ATTR) or with cardiomyopathy unrelated to amyloid (gray bars), and patients with 
amyloidotic cardiomyopathy due to ATTR, AL, or SSA (black bars). Requantified 
results from the indirect ELISA analysis by direct ELISA (A). Expansion of the SSA 
serum sample number in the revised data (B) showed an increased average serum CLU 
concentration in this group. (C) Serum from draw date no earlier than 2001. (D) 
Samples stored only at -80°C. Specimen depletion accounts for group sample number 
differences. **P < 0.01, ***P < 0.001; CMP =cardiomyopathy. 
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mg/mL, n = 98), although this CLU level for the larger group was still significantly lower 
than healthy controls (Figure 18B). Such a dramatic increase in the mean concentration 
of CLU prompted further analysis; SSA inter-assay variability results were ordered by 
date and examined. Older SSA sample draw dates showed very poor reproducibility 
across assays compared to more recent samples (data not shown). Analysis was restricted 
to samples whose draw date was ~ 2001, the date when the amyloid-negative CMP+ 
samples (from the laboratory of Dr. Flora Sam) were acquired from patients and 
subsequently stored at -80°C (Figure 18C). All amyloid CMP groups demonstrated an 
increase in CLU levels compared to the previous direct ELISA results. A further analysis 
was performed on only those patient sera stored continuously at -80°C from time of 
acquisition to the present (Figure 18D). The SSA cohort (n = 20) in this final study was 
no longer significantly different than healthy controls or non-amyloid CMP cohorts. 
Serum CLU levels of all experimental amyloid CMP specimens measured by direct 
ELISA showed a clear increase in concentration correlating with sample draw date 
(Figure 19A). Sub-group analyses for SSA, AL-CMP, ATTR-CMP, AL-no CMP, and 
ATTR-No CMP (Figure 19B, C, D, F, G) demonstrated the same sample draw date 
association with lower CLU levels found in older samples. Conversely, the no amyloid 
CMP+ group did not show a trend associated with sample draw date (Figure 19E). 
4.3 Summary 
In summary, m both indirect and direct ELISA analyses of patient sera, a 
consistent and significant trend toward lower levels of CLU associated with amyloid 
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Figure 19. Serum clusterin concentrations as a function of blood draw date. 
A relationship between CLU level and age of sample was analyzed. Concentration and 
blood draw date were plotted for samples from all amyloid CMP groups (A) and 
individual experimental cohorts (B-G). In the sera from patients with amyloidosis, CLU 
concentrations were directly related to sample date, i.e. the most recent samples had the 
highest level of CLU. This was not the case with the sera from patients with 
cardiomyopathy not related to amyloidosis (E) from Dr. Flora Sam. CMP = 
cardiomyopathy. 
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CMP was observed in the initial cohorts examined. On further evaluation of the data and 
specimen characteristics, it was determined that an association between serum CLU 
concentration and sample draw date was evident. CLU measurements were re-evaluated 
in samples that had been continuously stored at -80°C. In these samples, CLU levels 
were not reduced in samples from patients with amyloidotic cardiomyopathy compared to 
the controls. Thus, CLU should only be measured in samples stored continuously at 
-80°C; we assume CLU can also be measured accurately in freshly collected samples. 
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Chapter 5. CLU rs11136000 Genotyping in Systemic Amyloidosis 
5.1 Genotype Data and Correlation to Serum Clusterin Levels 
Genomic DNA from 213 amyloidosis patients and 31 commercially obtained 
controls was purified and quantified for CLU SNP rs11136000 analysis. It was 
hypothesized that this intronic, disease-associated SNP could have an effect on 
expression of the secreted form of CLU; a correlation analysis ofrs11136000 with serum 
CLU levels was the basis for this investigation. The TaqMan® SNP specific fluorescent 
probe assay was used to determine genotype status; the probe generated increasing F AM 
and/or VIC fluorescence with each PCR cycle and detection was accomplished by RT-
PCR monitoring (Figure 20A). Total fluorescence yield was normalized to no gDNA 
template controls and fluorophore signals were clustered into 3 groups corresponding to 
genotypes (Figure 20B). Homozygous CC and TT genotypes corresponded to VIC and 
FAM fluorescence respectively, whereas CT heterozygotes clustered with an 
approximately equal ratio ofVIC and FAM relative fluorescence units (RFU). Genotypic 
frequencies were determined for control samples (n = 31 ), amyloid positive samples (n = 
213) and amyloid sub-groups with and without CMP (amyloid-CMP, n = 168 and 
amyloid-No CMP, n = 45) (Table 3). 
Where serum CLU concentrations were available, control and experimental sera 
were grouped by genotypes and compared to levels of circulating CLU (Figure 21A-D). 
An allele-dose response trend was observed in the amyloid serum and specifically in the 
SSA group where lower serum CLU concentrations were associated with the presence of 
the C allele. Some samples used were from the old specimens. 
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Figure 20. Analysis of a common disease-associated CLU intronic single nucleotide 
polymorphism in patients with amyloidosis and controls. 
CLU rs11136000 SNP-specific (C/T) TaqMan® fluorescent probe measurements were 
obtained using F AM and VIC as the allele-specific probes. F AM homozygotes and VIC 
homozygotes correspond to CC (squares) and TT (circles) patient genotype clusters. 
Heterozygote CT (triangles) signals of both fluorophores were also observed. Pre- (A) 
and post-normalization (B) of the data with a no gDNA template control (NTC, black 
diamonds, panel A) are shown. 
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Table 3. CLU rs11136000 single nucleotide polymorphism genotype frequencies. 
Frequencies for CLU rsl1136000 genotypes were determined for no amyloid controls, 
amyloid specimens (pooled SSA, ATTR and AL), and amyloid cohorts sub-grouped by 
cardiomyopathy involvement. CMP = cardiomyopathy 
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CLU rs11136000 Genotype Frequencies 
Control Amyloid Amyloid Amyloid 
C:MP NoCMP 
N 31 213 168 45 
cc 0.35 0.33 0.32 0.36 
CT 0.49 0.51 0.52 0.46 
TT 0.16 0.16 0.16 0.18 
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Figure 21. CLU rs11136000 single nucleotide polymorphism allele-dose response. 
Serum CLU levels measured by indirect ELISA were correlated with genotype status in 
all sera, amyloid sera, control sera, SSA, where measurements were available. An allele-
dose response trend was observed in the amyloid serum and specifically in the SSA group 
where lower serum CLU concentrations were associated with the presence of the C allele. 
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Amyloid Serum CLU and 
rs1113&00 genotypes 
SSA Serum CLU and 
rs 1113600 genotypes 
5.2 Summary 
Genotype analysis for the intronic disease associated SNP rslll36000 was 
conducted using the SNP specific TaqMan fluorescent probe assay. Genotypes were 
determined for 213 amyloidosis patients and 31 age-matched controls. Comparative 
analysis of genotype status and mean serum CLU levels was conducted and an allele-
dose response trend was noted across multiple group analyses trending toward lower 
CLU levels associated with the presence of the C allele. However, this effect could not 
be validated because of the problems described with the serum analysis in the section 
above. Future studies with fresh samples will be required to determine whether 
rs11136000 genotype is associated with alteration in serum levels ofCLU. 
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Chapter 6. 
Proteins 
Preparation and Analyses of Serum Clusterin and Transthyretin 
For further investigation of the interactions between CLU and TTR, it was 
essential to obtain amounts of both proteins that would be sufficient for the planned 
biochemical and biophysical experiments. Recombinantly-derived TTR proteins were 
available in abundant supply and have been extensively characterized previously in our 
laboratory (Kingsbury et al., 2007). We pursued methodology and reagents that would 
allow us to purify CLU from human serum. 
6.1 G7 a-CLU-IgG1 Monoclonal Antibody Isolation and Functionality Testing 
Protein-A/G conjugated agarose was used to purify a-CLU-IgG1 from clarified 
G7 mouse hybridoma supernatant. Size exclusion chromatography by HPLC afforded 
purity determination of the isolated antibody sample. A single peak with a retention time 
of 8.398 min was observed (Figure 22). This was consistent with the expected size of 
IgG (~155 kDa); prior to the run, column calibration was performed with a reference 
protein, alcohol dehydrogenase (150 kDa), that exhibited a retention time of 8.5 min (data 
not shown). 
SDS-PAGE and immunoblotting against a recombinantly-derived CLU protein 
(rCLU) was performed under non-reducing and reducing conditions to compare antibody 
reactivity of the commercially-obtained H330 a-CLU polyclonal antibody (Figure 23A) 
and purified G7 a-CLU monoclonal antibody (Figure 23B). Purified G7 a-CLU IgG1 
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Figure 22. Analysis of purified G7 a-CLU IgG1 by size exclusion chromatography. 
The purity of isolated 07 antibody was assessed using size exclusion chromatography by 
HPLC. The sample was applied to an Agilent SEC-3 (3Jlm, 300A, 7.8 x 300 mm) 
column operating at a flow rate of 1 mL/min. Retention time for 07 retention time was 
measured at 8.398 min. Protein reference standards used for column calibration included 
alcohol dehydrogenase (150 kDa) which had a column retention time of8.500 min. 
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Figure 23. Immunoreactivity of G7 a-CLU IgG1 and recombinant clusterin. 
Non-reduced (lanes 1, 2, 4, 5) and chemically reduced (lane 3, 6) forms of rCLU were 
separated by SDS-PAGE and immunoblotted with the H330 polyclonal antibody (A) and 
the purified mouse monoclonal G7 a-CLU IgG1 (B). Immunoreactivities of the two 
antibodies were nearly identical; G7 a-CLU IgG1 recognition of the monomeric (36-39 
kDa), dimeric (72 kDa), and tetrameric (150 kDa) forms ofrCLU was demonstrated. 
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showed reactivity towards both non-reduced (75-80 kDa) and reduced (36-39 kDa) forms 
ofrCLU and was comparable in reactivity to the H330 polyclonal antibody. 
The G7 a-CLU monoclonal antibody was tested against whole serum using 
western blot and dot blot techniques (Figure 24). Reactivity against serum heterodimeric 
CLU (75-80 kDa), dimer-dimer, and high molecular weight multimeric forms of CLU (~ 
150 kDa) was evident on non-reducing SDS-PAGE (Figure 24A, lane 1). The results 
were similar when rCLU was used (Figure 24A, lane 3). Under reducing conditions, 
immunoreactivity of serum CLU (Figure 24A, lane 2) with the antibody was observed, 
but a different migration pattern was noted when compared to that obtained with rCLU 
(Figure 24A, lane 4). This appears to be an artifact associated with separating whole 
serum samples by SDS-PAGE under reducing conditions as purified forms of serum CLU 
demonstrates (Figure 25) . 
To further test G7 a-CLU antibody reactivity towards non-denatured forms of 
serum CLU, dilutions of serum were dotted onto a nitrocellulose membrane and probed 
with G7 a-CLU; 1% BSA was used as a negative control (Figure 24B). Serum:PBS 
dilution dependent reactivity was observed; no reactivity was evident in the blot 
containing the BSA control. Based on these observations, it was concluded that the G7 
a-CLU IgG1 antibody isolated from hybridoma supernatant was sufficiently pure and 
functional as it recognized both recombinant and serum forms of CLU. 
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Figure 24. Immunoreactivity of G7 a-CLU IgG1 and whole human serum. 
Control serum 1:20 in PBS (lanes 1, 2) and rCLU protein (lanes 3, 4) were separated by 
SDS-PAGE under non-reducing (lanes 1, 3) and reducing (lanes 2, 4) conditions for 
immunoblotting with G7 (A). In addition, serum diluted with PBS was tested by dotblot 
against the G7 antibody; BSA served as a negative control (B). 
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6.2 Human Serum Clusterin Purification and Assessment 
G7 a-CLU antibodies were used to generate an immunoaffmity column for the 
purification of human CLU from the pooled sera of healthy Caucasian male donors. 
From 100 mL of serum 7.56 mg of sCLU was purified using a 5 mL G7 immunoaffinity 
column. Serum was not completely depleted of CLU and saved for subsequent column 
applications. The purified serum CLU (sCLU) was analyzed by immunoblot under 
reducing conditions using the G7 IgG1 anti-human CLU antibodies (Figure 25A). The 
purified product, column flow through post-sample application, and pre-immunoaffinity 
column pooled sera are shown (Figure 25A, lanes 1-3). These data demonstrate almost 
complete depletion of CLU from the pooled serum sample (Figure 25A, lane 2); 
moreover, 1.6 f.lg of purified sCLU shows greater reactivity than that of the pre-column 
sample total protein load of 60 f.lg (Figure 25A, lanes 1 and 3). Incomplete disulfide 
reduction of the 75-80 kD sCLU heterodimer most likely accounts for the second band in 
the purified sCLU sample, while the reduced 36 kD a-chain and 39 kD ~-chain of sCLU 
run together in all three samples. Self-associated HMW forms of purified sCLU were 
observed by FPLC size exclusion chromatography which showed a major, broad peak 
and a shoulder corresponding to sizes ranging from >669 to ~200 kDa and 158 to 75 kDa, 
respectively (Figure 25B). These FPLC results were consistent with other laboratory 
findings noting a strong tendency for self aggregation when serum CLU is purified to 
homogeneity by immunoaffinity (personal communication with Mark Wilson PhD, 
University ofWollongong, Australia). 
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Figure 25. Immunochemical and chromatographic analyses of purified human 
serum clusterin. 
(A) Clusterin, immunoaffinity isolated from a pooled human serum sample, was analyzed 
by immunoblot with anti-CLU G7-IgG1 (lane 1) along with samples from the pre- (lane 
3) and post-column (lane 2) purification steps. (B) Size exclusion chromatography by 
FPLC of the purified sCLU showed a broad peak at elution volumes (25.3 to 36.0 mL) 
corresponding to 669-75 kDa. Protein absorbance of eluted fractions was measured at 
280 nm. Standard reference proteins used for column calibration were thyroglobulin 
(669 kDa), aldolase (158 kDa), and conalbumin (75 kDa) which had elution volumes of 
25.11, 32.31, and 36.01 mL, respectively. 
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SDS-PAGE analysis of purified sCLU, cross-linked by treatment with 
glutaraldehyde, showed Coomassie blue staining of protein bands corresponding to 
HMW (> 250 kDa) forms of the protein (Figure 26, lane 2). (See Section 6.3 below for 
further explanation ofthe TTR samples in this Figure.) Self-association of purified sCLU 
at neutral pH has been previously reported (Humphreys eta!., 1999) and we have noted 
this phenomenon in sedimentation velocity experiments performed on purified CLU (data 
not shown). Under denaturation and reducing conditions in the absence of cross-linking, 
purified sCLU displayed two major and several less prominent protein bands with 
Coomassie blue staining (Figure 26, lane 6). The most abundant form was at a position 
on the gel corresponding to ~37 kDa; this is consistent with the reduced form of sCLU 
composed of two subunits (a-chain, 36 kDa and P-chain, 39 kDa) that nearly equivalent 
electrophoretic migration endpoints. The second most abundant form occurred at a 
position corresponding to a size of ~60 kDa; a previous report suggested that this is a 
partially glycosylated form of sCLU that is uncleaved in the endoplasmic reticulum 
(Rizzi and Bettuzzi, 2010). Several less prominent bands were visible, including one at 
75-80 kDa which likely represents the incompletely reduced form of sCLU. 
Circulating human CLU is normally anN-linked glycoprotein. To test for the 
presence of glycosylation in our immunoaffmity purified sCLU, we treated the protein 
with PNGase-F (Figures 27 and 28). PNGase F is an endoglycosidase that cleaves the 
chemical bond joining the innermost N-acetylglucosamine and asparagine residues on N-
linked glycoproteins. Pre- (PNGase F-) and post-treatment (PNGase F+) samples were 
analyzed for molecular weight changes by SDS-PAGE with Coomassie blue (Figure 
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Figure 26. Electrophoretic analysis of purified human serum clusterin and 
recombinant transthyretin. 
Clusterin isolated from pooled normal human serum (lanes 2, 6) and rTTR proteins (lanes 
3-5 and 7-9) were electrophoresed by SDS-PAGE under cross-linking (lanes 2-5) and no 
cross-linking (lanes 6-9) conditions. The rTTR proteins tested were wild-type (Wt), 
monomeric (M, F87M/L110M), and L55P forms. 
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Figure 27. PNGase-F endoglycosidase treatment of purified serum clusterin 
confirms the presence of N-linked polysaccharides. 
Pre- and post-treatment samples from the reaction of sCLU with PNGase-F were 
separated by SDS-PAGE under reducing (DTT+) or non-reducing (DTT-) conditions and 
analyzed by Coomassie blue (A) and periodic acid-Schiff, PAS staining (B) for 
polysaccharides. PNGase-F has a mass of 36 kDa. 
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Figure 28. Immunoblot analysis of PNGase-F treated serum clusterin. 
Purified sCLU samples, pre- and post-digestion with PNGaseF, were immunoreactive 
against anti-human CLU antibodies. Samples analyzed previously by Coomassie blue 
and PAS staining were immunoblotted using (A) G7 mouse monoclonal IgG1 and (B) 
H330 rabbit polyclonal IgG antibodies against human CLU. 
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27 A) and polysaccharide presence by periodic acid-Schiff (PAS, Figure 27B). 
Moreover, immunoreactivity to G7 monoclonal IgG1 anti-human CLU (Figure 28A) and 
H330 polyclonal IgG anti-human CLU (Figures 28B) was assessed by immunoblot. 
In the presence of dithiothreitol (DTT), the disulfide-linked 75 kDa sCLU hetero-
dimer was reduced to a- (36 kDa) and ~-chains (39 kDa) which do not resolve as separate 
bands in this system (Figure 27A, lane 1). In addition, protein bands most likely 
resulting from incomplete reduction of the heterodimer (75 kDa) and a partially 
glycosylated sCLU (60 kDa, described above) were observed. Analysis of sCLU, using 
conditions that preserve disulfide bonds, demonstrated the presence and abundance of the 
75 kDa heterodimer, as well as the occurrence of the 60 kDa form and higher molecular 
or likely aggregated species (Figure 27 A, lane 3). In the samples that were not treated 
with PNGase F, PAS staining was observed for all major sCLU forms (Figure 27B, lanes 
1 and 3) and consistent with the Coomassie results (Figure 27 A, lanes 1 and 3). 
Enzyme treated sCLU samples showed molecular weight shifts of all major forms 
of sCLU (37, 60, 75, and ::=::150 kDa) as shown in Figure 27A, lanes 2 and 4 and the 
absence of PAS staining seen in Figure 27B, lanes 2 and 4. These results were as 
expected for enzymatic digestion of N-linked glycosylated residues from the purified 
sCLU product. Under reducing conditions, deglycosylated sCLU exhibited a much 
different electrophoretic migration pattern than the untreated protein; electrophoretic 
migration of the a- and ~-chains shifted from a single broad band corresponding to 3 7 
kDa for the glycosylated protein (Figure 24A, lane 1) to two resolved bands of ~25 kDa 
in size (Figure 24A, lane 2). Serum CLU oligosaccharide groups are heterogeneous and 
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present on each subunit; glycosylation accounts for 27-30% of the ~ subunit mass and 0-
30% of a subunit mass. Our observation of a and ~ chain resolution following 
deglycosylation of CLU was as expected. Interestingly, after PNGase F digestion, the 75 
kDa and 60 kDa forms of sCLU appeared to shift in molecular weight and migrate 
together at approximately 50 kDa (Figure 24A lanes 2 and 4). The extent of 
heterogeneous glycosylation of these CLU isoforms appears to be responsible for this 
observation. PNGase F has a mass of36 kDa. 
Immunoblot testing of the pre-treatment samples showed reactivity of the 
homotetrameric (75 kDa) and reduced (37 kDa) forms of sCLU with both the G7 
monoclonal IgG1 and H330 rabbit polyclonal IgG antibodies (Figure 28A and B, lanes 1 
and 3); no reactivity of the 60 kDa form was observed. In the PNGase F treated sCLU 
samples, the two major immunoreactive bands (at 25 and 50 kDa) appeared to be present 
in approximately the same relative proportion as the untreated protein, but both shifted to 
lower molecular weight forms (Figure 28A and 3B, lanes 2). These results demonstrate 
that the immunoaffmity purified sCLU is a clean preparation of protein and structurally 
consistent with previous reports. Providing these characterization data was important as 
it has been hypothesized that the proper functioning, i.e. the chaperoning capacity of 
sCLU, may be affected by the presence of glycosylation. 
6.3 Monomeric and Tetrameric Transthyretin Proteins 
The TTR double variant, F87M/L110M, is an engineered protein that occurs 
mostly as monomers (M-TTR) at neutral pH, i.e. the protein does not form TTR 
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tetramers. Monomeric TTR was purified and analyzed by chemical cross-linking and gel 
electrophoresis (Figure 26, lane 4). For comparison, wild-type (Wt) and L55P forms of 
rTTR, which normally occur as tetramers, were also purified and cross-linked with 
glutaraldehyde to be analyzed electrophoretically (Figure 26, lanes 3and 5). When 
cross-linked, Wt and L55P occurred mainly as 56 kDa forms corresponding to tetrameric 
TTR; minor amounts of dimeric TTR (~30 kDa) and a HMW (> 150 kDa) form were also 
observed (Figure 26, lanes 3 and 5). In contrast, the most abundant form of cross-linked 
M-TTR was observed at an electrophoretic migration endpoint consistent with TTR 
monomer (14 kDa); minor amounts of dimer (30 kDa), trimer (45 kDa), tetramer (56 
kDa), and HMW forms (> 150 kDa) were present as well (Figure 26, lane 4). In the 
absence of chemical cross-linking, all rTTR proteins displayed identical electrophoretic 
profiles, i.e. monomeric (14 kDa) TTR was the most abundant form present and minor 
amounts of dimeric (30 kDa) TTR were also observed (Figure 26, lanes 7-9). 
6.4 Summary 
The G7 mouse hybridoma cell line was utilized successfully for the production of 
a monoclonal anti-human serum CLU antibody. Assessment of G7 antibody purity and 
functionality were performed by HPLC and two immunoblot techniques, western blot and 
dot blot analyses. Yield of antibody was sufficient to generate a G7 immunoaffinity 
column which was used to purify CLU from pooled human serum. Milligram quantities 
of sCLU were prepared for use in studies of the protein with TTR. 
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Purity and structural assessments of the purified sCLU protein were accomplished 
usmg chromatographic, electrophoretic, and immunochemical techniques. Analyses 
demonstrated a clean preparation of protein with a mass consistent for native CLU ( ~ 7 5 
kDa) or individual subunits (~37 kDa) under reducing conditions. Moreover, purified 
sCLU was immunoreactive to anti-human CLU antibodies and treatment of the protein 
with an endoglycosidase demonstrated the presence of N-linked polysaccharides. 
Monomeric and tetrameric rTTR proteins were purified and quaternary structures 
confirmed by SDS-PAGE. It was demonstrated that monomeric (F87M/Lll OM) TTR 
did not form tetramers at neutral pH, while the Wt and L55P proteins were present 
mainly in tetrameric form. 
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Chapter 7. In Vitro Studies of Transthyretin Tetramer Stability 
7.1 Stability Differences in Wild-type and Variant Transthyretin 
Acidic conditions are well known to rapidly induce TTR tetramer dissociation, the 
initial step in the formation of amyloid fibrils; this provides an in vitro experimental 
system for TTR fibrillogenesis utilizing different TTR proteins. Furthermore, Congo red 
binding is a standard method for monitoring the formation of amyloid fibrils and this 
method was used as the readout for our acid-mediated rTTR fibril formation experiments. 
We investigated the differences in stability of several purified rTTR proteins 
usmg the acid-mediated fibril formation assay. Wild-type, and the amyloidogenic 
variants, V30A and V122I, were studied. In addition, the double variant Vl22IJT119M 
was tested to determine the effect of Tl19M, reported to be a protective or anti-
amyloidogenic variant (Coelho et al., 1993). All proteins have previously been shown to 
exist as tetramers of varying stability at physiologic conditions. 
Initially, the Vl22I rTTR variant was studied. Following 5 days under acidic (pH 
4.5) conditions, TTR had formed insoluble material which was collected and stained with 
Congo red. Light microscopic examination of the precipitated TTR showed Congo red 
binding with green birefringence when viewed under standard and polarized light, 
respectively (Figure 29C and D). These results were comparable to Congo red staining 
results obtained on cardiac amyloid deposits in tissue sections from a TTR-associated 
amyloidosis case (Figure 29A and B). 
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Figure 29. Congo red staining of ex vivo and in vitro amyloid. 
Light microscopy of cardiac amyloid deposits in autopsy tissue from a TTR-associated 
amyloidosis case stained with Congo red and viewed under standard (A) and polarized 
(B) light. In vitro generated rTTR-V122I amyloid fibrils formed stained with Congo red 
and viewed under standard (C) and polarized (D) light. 
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Wild-type, V30A, V1221, and V1221JT119M rTTR proteins were tested in the 
acid-mediated fibril formation assay. Congo red spectral wavelength scans of each rTTR 
protein were performed following the 5 day period. Compared to the spectrum of Congo 
red, all sample spectra were shifted toward higher wavelengths and a red shift in the 
maximum absorbance value for each variant was observed (Figure 30, left); this result 
indicated that Congo red was binding to amyloid fibril structures. A table of maximum 
absorbances for each sample is shown (Figure 30, right). The magnitude of each red 
shift measured at 540 nm correlated with reported stabilities of the rTTR variant 
tetramers (Hurshman Babbes et al., 2008), with V122I and V30A variants exhibiting the 
largest changes. Interestingly, the inclusion of the reported tetramer stabilizing residue, 
T119M, with Vl221 in the double variant TTR protein, showed a decreased red shift 
compared to the V1221. This suggested that the presence of T119M inhibits the fibril 
forming capability ofV1221. 
7.2 Transthyretin Tetramer Stability in the Presence of Small Molecule Binders 
Diflunisal and resveratrol are small molecules known to bind to TTR; diflunisal 
has been shown to stabilize TTR tetramers. The secondary structures of wt, V30A, and 
V122I TTR under physiological conditions were analyzed by CD to ensure that there 
were no structural differences among the proteins (Figure 31A). Far UV CD spectral 
analysis demonstrated nearly identical secondary structure profiles for all three proteins, 
i.e. overlapping spectra consisting mainly of ~-sheet conformations were observed. In 
the samples incubated with diflunisal or resveratrol, binding of the agent to TTR showed 
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Figure 30. Comparison of transthyretin variant fibril formation by Congo red 
spectral analysis. 
Wild type and 3 variants (V122I, V30A, and V122IIT119M) of TTR were used to form 
amyloid fibrils in vitro. Fibrils were suspended in Congo red and analyzed by 
wavelength scanning for dye binding, indicated by a red shift in absorbance spectra. 
Absorbance maximum wavelength values are shown in the table on the right. Enhanced 
Congo red binding was noted for V30A and Vl22I, amyloidogenic variants of decreased 
stability, while the presence of Tll9M with Vl22I appeared to stabilize TTR as there 
was less Congo red binding with this protein. 
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Figure 31. Secondary structural analyses of transthyretin binding to small 
molecules, diflunisal and resveratrol. 
(A) CD spectra of wild-type (wt) TTR and amyloidogenic variants, V30A and V1221 at 
pH 7.4 and 25°C. All three proteins exhibited nearly identical spectra indicating mainly 
~-sheet structure in their native tetrameric conformation. (B) CD spectra of the TTR 
variant, V30A (3.6 ).!M), incubated with diflunisal or resveratrol at 50 M excess for 2 hat 
room temperature. Amplitude differences indicated molecular interactions of both small 
molecules with the TTR tetramer. 
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CD signal changes as evident by fluctuating amplitudes at approximately 210 nm (Figure 
31B). These fluctuations could be from either an induced CD signal by the small 
molecules themselves upon binding, or from changes in TTR secondary structure due to 
binding of the small molecules. V30A CD spectra were chosen as a representation of 
similar observations that were made for the other TTR variants and the wild-type protein 
(data not shown). 
The tetramer stabilization effect of diflunisal was further examined in the context 
of pH, specifically at lower or acidic pH conditions that are known to accelerate the 
kinetics oftetramer dissociation and fibril formation. SDS-PAGE analysis ofV30A with 
and without diflunisal in solutions of pH from 7.0 to 3.6 was performed (Figure 32). In 
the absence of diflunisal, decreased amounts of tetramer with increased levels of 
monomer were observed as pH decreased (Figure 32A). However, solutions with 
diflunisal showed decreased tetramer dissociation to monomer with an increased amount 
of tetramer across decreasing pH conditions (Figure 32B). Additionally, the amount of 
HMW aggregated material in the wells at pH 4.0 and 3.6 was decreased with diflunisal 
treatment, suggesting that the kinetics ofV30A aggregation was delayed (Figure 32B). 
Acid-mediated amyloid fibril formation with V30A TTR in the presence of 
diflunisal was monitored by Congo red binding and spectral scanning. The results of this 
experiment clearly showed that the presence of diflunisal inhibited V30A amyloid fibril 
formation (Figure 33). A smaller spectral shift for the diflunisal treated V30A sample, 
compared to V30A alone, indicated a decrease in amount of amyloid fibrils. These data 
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Figure 32. Transthyretin tetramer stabilization by diflunisal. 
SDS-PAGE separation and silver stain analyses were performed on cross-linked V30A 
rTTR samples from 72 h incubation at 37°C under varying pH conditions in the absence 
(A) and presence (B) of 50 molar excess diflunisal. With no diflunisal, decreased levels 
of TTR tetramer and increased amounts of monomer, as well as high molecular weight 
species were observed. Conversely, for the samples treated with diflunisal from pH 7.0-
4.8, mainly tetramer and little or no monomer was observed; at the lower pH range (4.4-
3.6), while the monomer was abundant, there was an increased amount of tetramer 
compared to solutions with no diflunisal and little high molecular weight species were 
observed. 
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Figure 33. Diflunisal inhibits transthyretin amyloid fibril formation. 
Acid-mediated, in vitro amyloid fibril formation with V30A rTTR was monitored by 
wavelength scanning of TTR solutions containing Congo red. The presence of 50 molar 
excess diflunisal prevented V30A aggregation and amyloid fibril formation as indicated 
by the absence of a red shift in the spectrum (V30A + diflunisal). 
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provided clear evidence that diflunisal can inhibit in vitro amyloid fibril formation 
presumably by preventing TTR tetramer dissociation. 
7.3 Summary 
In vitro rTTR amyloid fibril formation under acidic conditions generated 
precipitated material that bound Congo red and exhibited apple-green birefringence under 
polarized light, a unique characteristic of fibrillar amyloid structures. Certain variant 
rTTR proteins with key amino acid substitutions (V122I, V330A) formed Congo red 
binding amyloid structures as demonstrated by spectral property changes of the bound 
dye. The amount of amyloid fibrils formed in vitro corresponded to the rTTR variant 
tetramer stability, suggesting that tetramer destabilizing residues altered the kinetics of 
tetramer dissociation and fibrillogenesis. Conversely, in the variants studied, the amino 
acid substitutions did not change the ~-sheet content or overall secondary structural 
characteristics of the proteins. The rTTR proteins we tested all bound to the small 
molecules, diflunisal and resveratrol, consistent with reported TTR binding properties. 
The binding of diflunisal to rTTR stabilized the tetrameric structure of the protein, i.e. 
diflunisal prevented dissociation of native TTR to monomers and inhibited in vitro 
formation of amyloid fibrils, as has been reported previously (Adamski-Werner et al. , 
2003; Baures et al., 1999; Baures et al., 1998). 
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Chapter 8. Biophysical Analyses of Clusterin Interactions with Transthyretin 
8.1 Thermal Denaturation of Transthyretin and Clusterin 
The thermal stabilities of wt, L55P, and monomeric (F87MIL110M) rTTR, and 
sCLU were examined using CD spectroscopy. It is important to note that wt and L55P 
TTR results reflect studies of the tetrameric protein, while the monomeric 
(F87M/LllOM) TTR data is for the unassociated subunits. A mild pH 5.0 condition was 
chosen to ensure both variant tetramer dissociation and monomer unfolding, while 
preserving sCLU functionality as it has been reported that sCLU maintains chaperoning 
function at mildly acidic pH (Hochgrebe et al., 2000). Figure 34A shows the far-UV CD 
spectra obtained for intact sCLU protein at 25°C (solid line) and the same sample 
subsequently heated to 98°C (dashed line) at a rate of2°C/min. The spectral data showed 
two minima at 210 and 220 nm, indicative of a-helix content. Heating of sCLU to 98°C 
led to marked spectral changes; the loss of a-helix secondary structure and transition 
toward an unfolded random coil configuration were observed. Figure 34B shows the far-
UV CD spectra recorded for the intact monomeric (monoTTR, F87M/L110M) rTTR 
protein at 25°C (solid line) and the same sample subsequently heated to 98°C (dashed 
line) at a rate of2°C/min. The monoTTR had a single minimum at 215 nm characteristic 
of ~-sheet structure. Heating to 98°C led to obvious alterations in the spectra data which 
indicated a loss of ~-sheet secondary structure and conversion to an unfolded random coil 
configuration. Since a change in CD signal was observed at 220 nm for both sCLU and 
rTTR proteins upon heating (Figure 34, vertical dotted line), this wavelength was 
142 
Figure 34. Thermal denaturation of clusterin and transthyretin monitored by 
circular dichroism. 
Far UV CD spectra of serum CLU (A) and monomeric rTTR (B) were recorded at 25°C 
before thermal stress and at 98°C after heating at 2°C/min. A significant loss of 
secondary structure was noted for both CLU and TTR as evidenced at 220 nm (gray line) ; 
reactions were subsequently monitored at 220 nm unless otherwise stated. Sample 
concentrations were 3.6 f.LM protein in 5 mM NazHP04, 100 mM potassium acetate, 50 
mM potassium chloride, pH 5.0. monoTTR =monomeric (F87M/L110M) rTTR. 
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chosen for monitoring changes in secondary structure during further thermal unfolding 
reactions. Thermal denaturation spectra were also recorded for wt and L55P TTR 
proteins at 25 and 98°C; both showed comparable ~-sheet secondary structure (data not 
shown). 
8.2 Thermal Unfolding ofEquimolar Transthyretin and Clusterin Mixtures 
Thermal unfolding reactions of wt, L55P, and monoTTR in the presence and 
absence of sCLU were studied by recording CD spectra in the far-UV at 220 nm. 
Secondary structural changes were indicated by fluctuations in CD signal for each rTTR 
variant, sCLU, and the equimolar mixtures; data for each TTR protein, sCLU, and the 
mixture were plotted together (Figure 35). The sCLU (blue solid squares) consistently 
showed a single phase transition at approximately 50°C followed by a plateauing and 
slight upward signal drift between 70-90°C. For wt TTR (Figure 35A, f"Illed circles), no 
loss of secondary structure was observed indicating a melting point (Tm) above 100°C. 
The equimolar mixture ofwt TTR and CLU (wtTTR+CLU, empty circles) exhibited only 
the sCLU low temperature melt phase which was not different from sCLU alone. L55P 
TTR (Figure 35B, filled diamonds) showed an initial unfolding, as indicated by a 
decrease in CD signal, beginning at 80°C; however, the unfolding was incomplete as no 
plateau was reached. The equimolar mixture ofL55P TTR and sCLU (L55P TTR+CLU, 
empty diamonds) showed the low temperature sCLU melt phase and the beginning L55P 
melt phase at 80°C. The monoTTR (Figure 35C, f"Illed triangles) displayed a single 
melt phase transition at 60°C followed by a complete plateauing of the data; these results 
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Figure 35. Thermal unfolding of transthyretin, serum clusterin, and equimolar 
mixtures. 
Samples ofwild-type (wt), L55P, and monomeric (mono, F87M/L110M) TTR, as well as 
CLU, and equimolar mixtures of each TTR and CLU were heated at a rate of 2°C/min 
with CD monitoring in the far UV at 220 nm. For individual protein samples, all CD 
spectra showed changes in signal as the temperature was increased indicating thermal 
unfolding of the proteins. For wt (A), L55P (B), and mono (C) TTR proteins, variant 
stability was monitored in the presence and absence of CLU. An additive effect of CD 
signals was observed consistently for all mixtures. 
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indicated a stable loss of secondary structure with the completed melt phase attained by 
~80°C. The equimolar mixture of monoTTR and sCLU (monoTTR+CLU, empty 
triangles) exhibited the low temperature sCLU melt phase and a unique higher 
temperature melt phase beginning at 80°C. These thermal unfolding data are consistent 
with previous studies of TTR protein stability showing wt > L55P > monomer. In 
addition, a constant additive effect of CD signals was observed in all equimolar mixtures 
of TTR and sCLU demonstrating not only consistency within the experiment but also the 
semi quantitative nature of monitoring total secondary structural changes. 
For the equimolar mixtures of rTTR and sCLU, the observed thermal unfolding 
CD spectral changes (at 220 nm) were compared to predicted sum values (Figure 36). 
The sum profiles are the additive composite spectral changes of each protein acquired 
independently and generated by spectral composite computation. For wt TTR+CLU, 
summed and observed thermal unfolding profiles exhibited nearly identical melt phase 
transitions (Figure 36A). The L55P TTR+CLU spectra comparisons showed slight 
fluctuations in CD signal at 220 nm; however, these differences were within experimental 
error limits (Figure 36B). For the monoTTR+CLU mixture, the summed and observed 
unfolding profiles showed a significant divergence beginning at 45°C and showing no 
overlap at higher temperatures (Figure 36C). This suggests a distinct effect of sCLU on 
the secondary structure of monomeric TTR. 
Comparison of thermal unfolding spectra (at 220 nm) for the equimolar rTTR and 
sCLU mixtures showed identical low temperature melt phases corresponding to unfolding 
of sCLU at 50°C (Figure 37). Wt showed a single low temperature melt phase 
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Figure 36. Predicted and observed thermal unfolding of equimolar transthyretin 
and serum clusterin mixtures. 
The observed secondary structural changes of each rTTR -sCLU mixture resulting from 
fast melt stress conditions (25-98°C at pH 5) were compared to the corresponding 
predicted sum values calculated as an additive composite of spectral data obtained at 220 
nm for each protein. Plotted curves for equimolar mixtures of (A) wild-type (wt), (B) 
L55P, and (C) monomeric (mono, F87M/L110M) TTR with sCLU are shown in black 
circles, green diamonds, and red triangles, respectively. Summed curves for wt, and 
L55P and monoTTR, are shown as gray diamonds and black circles, respectively. 
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Figure 37. Comparison of thermal unfolding data for equimolar mixtures of 
transthyretin and clusterin. 
The secondary structural changes of each rTTR-CLU mixture resulting from fast melt 
stress conditions (25-98°C at pH 5) were compared by plotting the CD data obtained for 
each sample at 220 nm. Curves for equimolar mixtures of wild-type (wt), L55P, and 
monomeric (mono, F87M/L110M) TTR with CLU are shown in black circles, green 
diamonds, and red triangles, respectively. While the mixtures containing wt and L55P 
show similar low temperature melt phases corresponding to sCLU, the monomeric TTR 
mixture sample showed less change in secondary structure for this low temperature 
phase. Some minor drift in wt signal can be observed as well as the beginning high 
temperature melt phase for L55P unfolding at 75°C that does not come to completion. 
Interestingly, the monomer containing sample showed a unique and complete high 
temperature melt phase from 80 to 90°C. 
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corresponding to sCLU unfolding, with slight signal drift that was also observed in the 
sCLU alone curves. Clear biphasic secondary structural transitions were evident in the 
L55P TTR+CLU and monoTTR+CLU mixtures, but only the monoTTR+CLU mixture 
sample exhibited a plateau at a higher temperature melt phase. The higher temperature 
melt transition in the L55P TTR+CLU mixture corresponds to the L55P tetramer melt 
phase. Interestingly, the monoTTR+sCLU mixture had a higher temperature melt phase 
transition, from 20°C and higher, than the monoTTR protein alone. 
To compare of the monoTTR, sCLU, and monoTTR+CLU melt profiles, data was 
transformed to fraction unfolded and scaled together (Figure 38A). Serum CLU (filled 
squares) and monoTTR+sCLU (empty triangles) showed identical low temp melt phases 
corresponding to sCLU unfolding. The monoTTR+sCLU higher temperature melt phase 
indicated retention of secondary structure in the mixture. These data suggest that there is 
greater protein structural stability in the mixture of the two proteins compared to either 
sCLU or monomeric TTR alone. As sCLU and monoTTR unfold simultaneously, 
molecular interactions may help to stabilize secondary structures and generate a unique 
complex with a higher melting temperature than either protein alone. Melting 
temperatures (Tm), determined from peak positions in the first derivatives of the CD 
data, further illustrated the presence of a high temperature melt phase in the mono-
TTR+sCLU mixture (Figure 38B). Tm values were calculated at 48°C for sCLU, 60°C 
for monoTTR, and 47°C and 84°C for the monoTTR+CLU mixture. 
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Figure 38. Effect of clusterin on thermal unfolding of transthyretin monomers. 
(A) Melting curves for monomeric TTR (mono, F87M/L110M), clusterin, and an 
equimolar mixture of the proteins were constructed from CD data recorded at 220 nm of 
the samples heated continuously from 25-98°C (pH 5); data acquisition continued until 
output was unchanging. The data were transformed and scaled together as fraction of 
unfolded protein. (B) The apparent melting temperatures (Tm) for samples were 
determined to be peak maxima obtained from first derivative calculations of the melting 
curve data. CLU alone (blue line) and the monoTTR-CLU mixture (red dashed line) 
exhibited similar melting curves with a lower temperature, structural transition phase (Tm 
= 47°C) and a stabile plateau at ~60°C. Monomeric TTR alone (solid red line) showed a 
single structural transition phase with a Tm = 60°C and a plateau at ~80°C. The mixture 
sample also displayed a second unique, higher temperature, structural transition phase 
(Tm = 84°C). 
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8.3 Summary 
Thermal stability testing of tetrameric and monomeric forms of rTTR, and sCLU 
demonstrated marked losses of protein secondary structure in monomeric rTTR 
(F87M/L110M) and sCLU on heating; less structural instability was noted for L55P and 
wt TTR. Secondary structural changes were monitored by comparing the CD signals of 
each rTTR, sCLU, and an equimolar mixture of the two proteins. Fluctuations in spectral 
data among the sample sets demonstrated clear stability differences of TTR proteins, 
particularly between the tetrameric and monomeric forms. Complete monomeric TTR 
unfolding was observed, while tetrameric forms of TTR were not fully denatured even 
under extreme thermal stress, i.e. heating to 98°C. Interestingly, a high temperature melt 
phase resulted when a mixture of sCLU and monomeric TTR was subjected to thermal 
stress. This unique high temperature secondary structure transition phase was not 
observed in the tetrameric TTR and sCLU mixtures, indicating a stabilization of 
monomeric TTR by sCLU. Melting temperatures were determined for all completed 
structural transitions. 
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Chapter 9. 
of Clusterin 
Biochemical Analyses of Transthyretin Oligomerization and Effects 
An in vitro approach was undertaken to investigate the capacity for CLU to 
recognize misfolded forms of rTTR. Using wt rTTR, the consistent and controlled 
unfolding, oligomerization, and amyloid fibril formation of the tetrameric protein was 
investigated. Briefly, TTR tetramer dissociation in a cold acidic solution (1 0 mM HCl, 
pH 2.0, 4°C) and monomer aggregation with salt (100 mM NaCl) was accomplished 
using a protocol adapted from the literature and described in the Methods section. A 
novel approach to observe and characterize hypothesized CLU:TTR interactions was 
undertaken using SPR biosensor technology for real time binding analysis. 
9.1 Rapid Generation and Characterization of High Molecular Weight 
Transthyretin Oligomers 
SDS-PAGE analysis was performed on chemically cross-linked wt rTTR samples, 
taken at various time points during the oligomerization assay (described in the preceding 
paragraph). Results of the study demonstrated the rapid formation of high molecular 
weight (HMW) forms of rTTR (Figure 39A). A clear transition from the 56 kDa native 
TTR tetramer (0 min) to HMW TTR oligomers was observed within 60 min. 
The immunoreactivity of the wt rTTR HMW species with the All anti-oligomer 
antibody was tested. This polyclonal antibody specifically recognizes amyloidogenic 
oligomers of A~, a-synuclein, and Islet amyloid polypeptide (lAPP), but not native or 
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Figure 39. Electrophoretic and immunochemical analyses of transthyretin 
oligomers formed by rapid acid-mediated aggregation. 
(A) Wild-type TTR samples at various time points in the rapid, acid-mediated oligomer 
formation assay were cross-linked with glutaraldehyde and analyzed by SDS-PAGE. 
Two types of high molecular weight (HMW) TTR oligomers were observed in the 5-60 
min samples; separation of ~250-500 kDa (HMW-1) and > 500 kDa (HMW-2) 
oligomeric species were visible between the top of the 10% resolving gel and 5% stacker 
gel. Native wtTTR was run in lane 1 as a reference (B) TTR samples from the same 
reaction time points were dotted on to nitrocellulose and probed with anti -amyloid 
oligomer antibody (All). Immunoreactivity of the samples increased as the TTR 
aggregation reaction proceeded. The most intense reaction was noted for the sample at 
240 min and a loss of reactivity was observed at 24 h due to structural transitions during 
oligomerization. A~ 1-40 was used as a positive control. 
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fibrillar forms of these proteins (Glabe, 2004; Kayed et al., 2003). Oligomerization assay 
samples were again removed at various reaction time points, neutralized, dotted to nitro-
cellulose, and probed using the All anti-oligomer antibody (Figure 39B). Increasing 
All immunoreactivity was observed at time points up to 240 min of the wt rTTR 
aggregation reaction. These data suggest that the HMW oligomers observed by gel 
electrophoresis are amyloidogenic oligomers of wt TTR. 
Wt rTTR secondary structural changes during the oligomerization reaction were 
monitored using CD (Figure 40). A transition of the high ~-sheet content structure of 
native TTR tetramer to random coil configurations was observed after 4 days of slow acid 
tetramer dissociation and monomer unfolding (black to dotted red spectra). Upon 
addition ofNaCl to the reaction, a partial transition to ~-sheet structure and increased ~­
sheet content over time was observed. These data indicated that TTR had undergone 
dynamic structural changes during formation of HMW oligomeric species without 
reformation of native structure. 
It was important to confirm that the oligomerization reactions were on a pathway 
leading to the formation of amyloid fibrils . Late stage oligomerization reaction solutions 
were tested for binding with Congo red. It was demonstrated that samples from the 
oligomerization assay after 5 days showed a red shift in maximum absorbance ( 483.25 to 
489.50 nm), while a solution of TTR tetramer did not show any dye binding (data not 
shown). 
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Figure 40. Transthyretin oligomerization reaction analyzed by circular dichroism 
spectroscopy. 
Oligomerization of wild-type TTR (wtTTR) was performed at pH 2, and 25°C, using 10 
mM HCl, and 100mM NaCl. The secondary structure of wtTTR at several time points 
(15, 60, and 105 min, and 17 h) during the reaction was monitored by CD. A loss of 
native tetrameric P-sheet content, as seen in the wtTTR native sample (black line), and a 
transition to random-coil configuration occurred after acid treatment (wtTTR in HCL, 
dashed red line). A subsequent transition toP-sheet structure upon addition ofNaCl and 
accumulation of P-sheet content over time was observed. 
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9.2 Surface Plasmon Resonance Biosensor Detection of Transthyretin Oligomers 
and Interactions with Clusterin 
SPR biosensor detection was used to characterize surfaces to which the previously 
described native or oligomeric forms of wt rTTR had been covalently bound using amine 
coupling chemistry. We used diflunisal and Congo red to characterize the TTR modified 
surfaces (Figure 41A-D). An observed decrease of diflunisal binding with a 
corresponding increase in Congo red binding was measured as a change in Response 
Units (RU) in the SPR sensograms. These units are directly proportional to the 
accumulation of mass on the surface of the detector over time during the injection phase 
(Figure 41A and B: diflunisal = 0-60 sec; C and D: Congo red= 0-120 sec). The 
dissociation phase follows injection and loss of small molecule mass from surfaces can 
be observed (Figure 41A and B: diflunisal = 60-100 sec; C and D: Congo red= 120-
200 sec). The raw data were plotted as colored lines which were fitted using BioRad 
ProteOn Manager software with the most conservative Langmuir 1:1 (analyte:ligand) 
interaction model indicated by the black line. Various models were available for 
sensogram data fitting to determine proper binding reaction kinetics. 
Recombinant CLU was passed over the native and oligomeric TTR surfaces 
(Figure 42). Concentration-dependent binding of CLU to the 24 h TTR oligomerization 
surface was observed during the injection (0-300 sec) phase (Figure 42B). No rCLU 
binding events took place with native (tetrameric) TTR surface (Figure 42A). It is 
important to note that the RU for binding, although low, did demonstrate a concentration-
dependent effect that was consistent with the accumulated mass of rCLU during the 
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Figure 41. Characterization of native and oligomeric forms of transthyretin by 
surface plasmon resonance. 
Diflunisal and Congo red binding to tetrameric and oligomeric forms of wild-type rTTR 
were assessed using SPR. Native TTR tetramer binding to diflunisal (A) and little to no 
interaction with Congo red (C) were observed; oligomers of wtTTR (from the 24 h 
aggregation reaction time point) showed a decreased interaction with diflunisal (B) and a 
concentration-dependent increase in binding to Congo red (D). 
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Figure 42. Analyses of clusterin and transthyretin interactions by surface plasmon 
resonance (Langmuir 1:1 Model). 
CLU binding to native and oligomeric forms of wtTTR was tested usmg two 
concentrations of CLU, 200 and 400 nM. The sensogram data was fitted to a 
conservative Langmuir 1:1 (analyte:ligand) interaction model. No binding of CLU to 
native TTR ligand (A) was observed. A concentration-dependent and stable binding of 
CLU to TTR oligomers (from the 24 h aggregation reaction time point) was evident (B). 
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injection phase. In addition, the dissociation phase was quite slow indicating that the 
rCLU:TTR interaction at the surface was stable in nature. 
Subsequent CLU:TTR interactions were modeled usmg more sophisticated 
algorithms available in the BioRad ProteOn Manager software analysis tools (Figure 43). 
Here, heterogeneous ligand data fitting was used with the assumption that the rCLU 
analyte can recognize multiple TTR ligand moieties on the surface. Using this model, the 
RU was low, but again demonstrated rCLU binding in a concentration-dependent 
manner. The kinetics of these association and dissociation curves were determined and 
results are shown in Table 4. For accurate determination of kinetic parameters, it was 
recommended that at least 4 concentrations of analyte be used (BioRad technical training 
seminar). Additional CLU binding data could not be afforded given the limited amount 
of rCLU available. Each sensogram represents an individual analyte injection experiment 
at multiple concentrations. 
9.3 Monitoring Transthyretin Oligomerization in the Presence of Clusterin by 
Thioflavin T Binding 
Under acidic conditions, TTR tetramer dissociation and amyloidogenic oligomer 
formation occurs, a process that can be monitored by thioflavin T (ThT) binding. An 
increase in fluorescence is observed when ThT binds to the exposed hydrophobic 
moieties of amyloidogenic oligomers. A TTR oligomer and fibril formation assay 
performed at pH 5.0 was established. TTR solutions at 0.56 or 0.28 f.!g/mL 
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Figure 43. Analyses of clusterin and transthyretin interactions by surface plasmon 
resonance (Heterogeneous Ligand Model). 
SPR binding data from the oligomeric TTRJCLU experiment was replicated and 
recalculated using a Heterogeneous Ligand interaction model for best fit. Oligomeric 
TTR samples (n=2) from 2 h (A) and 24 h (B) aggregation reaction time points showed 
similar binding kinetics and stable associations to CLU (200 and 400 nm) (n=2). 
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Table 4. Kinetic analyses of clusterin and oligomeric transthyretin interactions 
from surface plasmon resonance data. 
The association (ka) and dissociation rate (k!) constants, and dissociation equilibrium 
constants (KD) for the SPR sensogram data are shown. The data were calculated using 
the Langmuir 1: 1 and Heterogeneous Ligand Models. 
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Parameter 
ka (1/M s) 
~ (1/s) 
KD (M) 
langmuir 
1:1 Model 
Native 
Tetra mer 
1.24 X 101 
1.05 X 103 
8.42 X 101 
langmuir 
1:1 Model 
24h lTR 
Oligomer 
4.34 X 103 
6.59 X 1CJ4 
1.52 X 10-7 
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Heterogeneous 
ligand Model 
24h lTR 
Oligomer 
1.75 X 104 
8.54x 10-4 
4.89 X 10-8 
(physiological concentrations) were incubated with either 50 M excess of the TTR 
tetramer stabilizer diflunisal or 1: 1 molar equivalents of sCLU at pH 7.2 prior to 
acidification (pH 5.0) of the solutions. This change in pH from 7.2 to 5.0 represents time 
0 (to) in all fibril formation assays. Three TTR variants of decreasing tetramer stability 
were tested; wt, L55P and monomeric (F87M/L11 OM) TTR, respectively. 
TTR oligomer and fibril formation continuous monitoring and endpoint analyses 
were performed with ThT binding performed in triplicate for each condition (Figure 
44A-D). TTR solutions at pH 5.0 were made basic (pH 8.0), and ThT was subsequently 
added to the solutions at various time points from 0 to 72 h. This step was added in an 
attempt to optimize the signal to noise ratio and fluorescence quantum yield of Th T. 
Fluorescence data were normalized to parallel blank buffer-only reactions with and 
without treatments of diflunisal and sCLU. In the wt samples (Figure 44B), there was no 
difference in total fluorescence change. Interestingly, for L55P it appeared that there was 
enhanced ThT binding in the presence of sCLU, while diflunisal abolished all ThT 
fluorescence increases over 72 h (Figure 44C). Analysis of ThT binding to monomeric 
TTR showed higher background and diflunisal treatment exhibited the greatest increase 
in fluorescence (Figure 44D). These results for Monomer were unexpected and warrant 
further investigations. 
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Figure 44. Effects of diflunisal and clusterin on transthyretin amyloid fibril 
formation by thioflavin T binding fluorescence. 
Wild-type (wt), L55P, and monomeric (Monomer, F87M/L110M) TTR samples, 
untreated or pre-treated with diflunisal (100 M excess) or serum CLU (7.2 ).lM) were 
used in the amyloid fibril formation assay, i.e. incubated for 72 hat pH 5.0; samples were 
removed from the assay at several reaction time points and analyzed by ThT binding 
fluorescence. (A) In the absence of diflunisal or CLU (No treatment), TTR proteins 
showed varying amounts of ThT binding with the highly unstable monomeric variant 
exhibiting the greatest change in fluorescence over time. (B) Treated and untreated wt 
TTR exhibited no change in ThT binding. (C) For L55P, a decrease in fluorescence was 
observed when diflunisal was present; an increase was noted in the samples containing 
CLU. (D) Monomeric TTR showed a decrease in signal for the CLU treated samples 
while the greatest ThT fluorescence change was noted in the samples with diflunisal. 
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9.4 Effect of Clusterin on Tetrameric and Monomeric Transthyretin 
Aggregation 
Wild-type, L55P, and monomeric (F87M/L110M) rTTR samples from the acid-
mediated fibril formation reactions were removed at various time points, chemically 
cross-linked, separated using SDS-PAGE, and immunoblotted for TTR or CLU (Figures 
45-47). Differences in structural stability, i.e. amount of TTR tetramer, for the three 
proteins were observed; wt samples showed tetramer present under all conditions (Figure 
45A), while L55P featured a decreased amount of tetramer over time (Figure 45B), and 
Monomer demonstrated no tetramer present in the absence of treatment (Figure 46). Pre-
treatment of TTR solutions with diflunisal stabilized the L55P tetramer and more 
interestingly, forced the formation of tetramerized Monomer at time 0 hr (Figures 45 
and46). Pre-treatment of TTR samples with sCLU showed novel TTR immunoreactive 
bands at regions of the gel indicating high molecular weight (HMW) aggregates (Figure 
45 and 46). L55P and Mono TTR showed a decrease in HMW-1 band intensity and an 
increase in HMW-2 band intensity as aggregation time increased (Figure 45B and 46). 
Immunoreactivity to sCLU was also observed for HMW-1 and HMW-2 bands with the 
same pattern of intensity changes as that observed for TTR reactivity (Figure 47). 
Interestingly, both L55P and Mono TTR, pre-treated with sCLU, showed persistent 
monomeric band intensity over time. Not only did TTR appear to colocalize with sCLU 
on the immunoblots, but sCLU pre-treatment appeared to stabilize a monomer-aggregate 
TTR equilibrium featuring an absence of tetrameric intermediates under the conditions 
used in the acid-mediated fibril formation assay. 
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Figure 45. Effects of clusterin and diflunisal on transthyretin tetramer stability and 
aggregation by immunoblot analyses. 
Wild-type (A) and L55P (B) rTTR proteins, untreated or pre-treated with diflunisal (Dif) 
or serum CLU (sCLU), were used in the amyloid fibril formation assay, i.e. incubated for 
72 hat pH 5.0 and 37°C. Samples were removed from the assay at several reaction time 
points (0, 5, 24, 48, and 72 h), cross-linked with glutaraldehyde, electrophoresed on SDS-
p AGE gels, and immunoblotted for TTR. (A) In the wt samples, tetramer, dimer, and 
monomer forms of TTR were present under all conditions with increased amounts of high 
molecular weight species (HMW-1 and -2) noted in samples with CLU. (B) The L55P 
samples showed decreasing levels of TTR tetramer over time; diflunisal treatment of 
L55P showed stabilization ofthe TTR tetramer, while the presence ofCLU resulted in an 
increase of monomeric and HMW -2 forms of TTR over time, and a decreased level of 
tetramer decreases. 
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Figure 46. Effects of clusterin and diflunisal on transthyretin monomeric stability 
and aggregation by immunoblot analyses. 
Monomeric (F87M/L 11OM) rTTR, untreated or pre-treated with diflunisal (Dif) or serum 
CLU, was used in the amyloid fibril formation assay, i.e. incubated for 72 hat pH 5.0 and 
37°C. Samples were removed from the assay at several reaction time points (0, 5, 24, 48, 
and 72 h), cross-linked with glutaraldehyde, electrophoresed on SDS-PAGE gels, and 
immunoblotted for TTR. Monomeric TTR showed no tetramer present in the absence of 
treatment; forced tetramerization at time 0 hr in the presence of diflunisal was noted. 
Monomer in the presence of CLU demonstrated a decreased level of the smaller (~250-
500 kDa) high molecular weight forms ofTTR (HMW-1) and an increased amount ofthe 
larger (> 500 kDa) high molecular weight species (HMW -2) over time. 
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Figure 47. Effect of aggregated transthyretin on clusterin by immunoblot analyses. 
Wild-type (Wt), L55P, and monomeric (Mono, F87M/L110M) TTR samples, pre-treated 
with serum CLU (7.2 !lM) were used in the amyloid fibril formation assay, i.e. incubated 
for 72 hat pH 5.0 and 37°C. Samples were removed from the assay at several reaction 
time points (0, 5, 24, 48, and 72 h), cross-linked with glutaraldehyde, electrophoresed on 
SDS-PAGE gels, and immunoblotted for CLU. The most abundant forms of CLU in all 
samples appeared as high molecular weight (HMW) species. The Wt TTR samples 
showed little change in the relative amounts ofHMW-1 or HMW-2 over time. However, 
for the L55P and monomeric TTR samples, while the HMW-1 form of CLU was most 
abundant at time 0, the amount ofHMW-2 increased dramatically in samples from longer 
reaction time points corresponding to increased levels of aggregated TTR. 
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9.5 Summary 
Under acidic conditions, rTTR was shown to aggregate and forni HMW 
oligomers as demonstrated by cross-linking and SDS-PAGE analysis with Coomassie 
staining. These HMW TTR oligomers were immunoreactive against the All anti-
amyloid oligomer antibody during the early aggregation stages. Secondary structural 
changes in rTTR during oligomerization complimented observed molecular weight 
changes and All reactivity, but also demonstrated a conformational conversion of the 
oligomers toward an increasing P-sheet structure over time, consistent with amyloid fibril 
formation. Recombinant CLU was shown to bind to oligomeric and aggregated forms of 
rTTR, but not to native TTR tetramer by SPR analysis. 
Aggregation reactions showed an increase in ThT binding over 72 h for L55P and 
Mono TTR. Treatment L55P with diflunisal prevented formation of ThT -binding forms 
of the protein, while sCLU appeared to enhance ThT binding. Mono TTR treated with 
diflunisal showed increased ThT binding, while sCLU appeared to suppress formation of 
ThT -binding aggregates. 
SDS-PAGE and western blot analyses demonstrated diflunisal stabilization of the 
L55P tetramer and actually appeared to force some Mono TTR into a tetrameric state. 
L55P and Mono TTR treated with sCLU both showed the formation ofHMW aggregates 
that were immunoreactive for both TTR and CLU. Interestingly sCLU treatments also 
stabilized the presence of monomeric TTR across 72 h of aggregation, where monomer 
was rapidly lost when sCLU was absent. 
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Chapter 10. Influence of Clusterin on Transthyretin Amyloid Fibril Formation 
10.1 Transthyretin Fibrillogenesis Study Using Congo Red Spectral Analysis 
Finally, TTR samples from the pH 5.0 acid-mediated amyloid formation assays 
were analyzed after a 10 day incubation period using the quantitative CR binding spectral 
shift method to measure endpoint amyloid fibril formation (Figures 48 and 49). Spectral 
data obtained for wt, L55P, and Mono rTTR proteins relative to CR buffer are shown 
(Figure 48A). The data indicated that L55P and Mono TTR had formed amyloid fibrils 
which bound to Congo red; spectral changes were evident for these variants relative to 
Congo red alone and wt TTR. In the near visible wavelength region at approximately 
420 nm, and the spectra 'shoulder' region at approximately 540 nm, increasing 
absorbance values were noted; these were due to light scattering caused by fibrils 
suspended in solution. The increased turbidity with a lack of a Congo red shift for wt 
TTR may indicate only minor amorphous aggregate formation under the given 
conditions. Moreover, for L55P and Mono TTR, the results obtained in these spectral 
regions in combination with the observed marked red shifts indicate that greater amounts 
of fibrils were formed with both of these proteins. BSA, sCLU, diflunisal, and Congo red 
buffer negative controls for the experimental treatments showed no significant Congo red 
binding after 10 days of incubation at pH 5.0 and 37°C (Figure 48B). 
10.2 Effect of Clusterin on Transthyretin Fibril Formation 
Wild-type TTR showed little Congo red binding, i.e. the spectral absorbance 
characteristics ofwt were nearly identical to that of Congo red alone (Figure 49A). 
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Figure 48. Congo red spectral analysis of transthyretin amyloid fibrils formed in 
vitro. 
(A) Wild-type (Wt), L55P, and monomeric (Mono, F87M/L110M) rTTR and (B) several 
controls including diflunisal (Dif), serum CLU, and bovine serum albumin (BSA) were 
used in the amyloid fibril formation assay, i.e. incubated at pH 5.0 and 37°C. After 10 
days, samples were suspended in Congo red solution and assayed for continuous 
absorbance measurements between 400-600 nm. A red shift spectral change which 
indicates Congo red binding and thus, the presence of amyloid fibrils, was observed in 
the L55P and monomeric TTR samples, but not the wt protein. The monomeric variant, 
the least stable of the TTR proteins, exhibited the greatest spectral shift indicating the 
greatest amount of amyloid formation. Little to no red shift was observed in any of the 
controls. 
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Figure 49. Effect of clusterin on in vitro transthyretin amyloid fibril formation. 
Wild-type (Wt), L55P, and monomeric (Mono, F87M/L110M) rTTR proteins, untreated 
or pre-treated with either diflunisal (Dif), serum CLU, or bovine serum albumin (BSA) 
were used in the amyloid fibril formation assay, i.e. incubated at pH 5.0 and 37°C. After 
10 days, samples were resuspended in Congo red solution and assayed for continuous 
absorbance measurements between 400-600 nm. The wt protein showed little fibril 
formation with a small red shift noted (A), while markedly increased spectral changes 
were noted for L55P and monomeric TTR. While pre-treatments with diflunisal or BSA 
showed little effect on preventing amyloid fibril formation in the L55P and monomeric 
TTR samples, the presence of CLU appeared to decrease the amount of Congo red bound 
structures in solution. 
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When sCLU, BSA, or diflunisal were added to wt TTR, the spectral changes observed 
seemed to reflect similar maximum absorbance shifts, but with a general decrease in light 
scatter (Figure 49A). Wt TTR tetramer has previously been shown to only dissociate 
and form amyloid fibrils at pH 4.5 or less (Lai et a/., 1996). Given the current reaction 
conditions, the observed effect appears to be due to mild amorphous aggregation and not 
fibril formation. 
Both L55P and Mono TTR variants exhibited marked Congo red binding shifts in 
absorbance spectra, with Mono TTR demonstrating the greatest Congo red binding 
(Figures 49B and C). Pre-treatment of samples with diflunisal did not appear to be 
effective at preventing fibril formation at this extended 10 day time point (Figure 49). 
Addition of sCLU to the aggregation reactions clearly caused a decreased amount of 
Congo red binding in both the L55P and Mono TTR reaction samples (Figures 49B and 
C). It was also noted that sCLU decreased the amount of light scatter in both the far and 
near visible light regions. BSA control treatments of L55P and Mono TTR had no effect 
on inhibiting amyloid fibril formation, i.e. red shifts in Congo red spectra of these 
samples were observed (Figure 49B and C). Determination of bound Congo red 
concentrations in fibril solutions shows that in fact diflunisal and CLU decreased the 
concentration of bound Congo red to L55P and monomeric TTR (Figure 50). BSA 
showed no effect on the amount ofbound Congo red in solutions ofL55P and monomeric 
TTR fibrils. 
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Figure 50. Quantitative Congo red binding analysis of transthyretin amyloid fibrils 
formed in vitro. 
The concentration of bound Congo red in solutions of rTTR amyloid fibrils treated with 
diflunisal, sCLU or BSA after 10 day incubation. Each sample is normalized to the 
Congo red spectrum of the treatment negative control. The amount of bound Congo red 
in solution for both L55P and monomeric TTR decreases with diflunisal and CLU 
treatments. Treatments with BSA show no effect on Congo red binding to amyloid fibrils 
formed in vitro. 
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10.3 Summary 
The rTTR fibril formation assay, performed at pH 5.0 with 10 day incubation at 
37°C, generated Congophillic amyloid structures when L55P or Mono TTR proteins were 
used. This was evident by a significant shift in Congo red spectra of the reaction 
products relative to Congo red alone. Pre-treatment of the unstable TTR variants with 
sCLU inhibited amyloid fibril formation. 
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Chapter 11. Discussion 
11.1 Amyloid Deposits Contain Clusterin 
These studies report that CLU is present in amyloidotic tissues derived from 
patients with SSA, ATTR, and AL amyloidosis. Our investigations demonstrate the 
specific association of CLU with fibrillar deposits found in cardiac tissues from cases 
featuring three different forms of systemic amyloid disease. In addition, we have shown 
that the presence of CLU in amyloid deposits is not restricted to cardiac tissues, as we 
detected the association in an amyloid infiltrated renal biopsy specimen from an AL 
amyloidosis case. Furthermore, in the cardiac tissue studies, we determined that 
increased levels of CLU occurred in the specimens from cases featuring TTR- and LC-
associated cardiomyopathy. It is possible that plasma circulating CLU may be the source 
of the CLU incorporated into amyloid deposits found in the heart or elsewhere; 
alternatively, the deposited CLU may come from the affected organ and/or tissue as a 
result of local up-regulation and secretion of the protein. Interestingly, it appeared from 
our histopathologic results that intracellular CLU levels were elevated in the 
cardiomyocytes of LC infiltrated amyloid tissue, indicating a possible cellular toxicity 
and localized response to LC in the heart. This is the first report identifying the presence 
of CLU in amyloid deposits from cases of SSA, ATTR and AL amyloidosis, and showing 
the co-localization of CLU with the amyloid fibril proteins, TTR and LC, in cardiac 
specimens. 
From the histologic and immunochemical data, it seemed evident that CLU was 
present in amyloid deposits. However, we sought to further understand the nature of this 
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occurrence. There is strong evidence from the literature to suggest that accessory 
molecules, consistently found associated with amyloid deposits (irrespective of the 
amyloid protein), play an important roles in fibril formation kinetics and stability 
(Alexandrescu, 2005). Amyloid P-component and glycosaminoglycans are two specific 
examples. In vitro evidence suggests that amyloid P-component accelerates Af3-42 
amyloid fibril formation and enhances stability (Mold et al., 2012). The sulfated GAG 
heparin, was shown to accelerate TTR aggregate formation with enhanced conversion of 
monomeric TTR to oligomeric species (Bourgault et al., 2011). This study also showed 
added resistance of aggregated TTR to proteinase K proteolysis, supporting a role for 
GAGs in the stabilization of TTR amyloid fibrils (Bourgault et al., 2011). We 
hypothesized that CLU might be another such accessory molecule. It was demonstrated 
in the fibril extraction experiments that ex vivo TTR amyloid fibrils were enriched with 
CLU. In the process of obtaining amyloid fibrils, proteins and other biomolecules that 
are associated with the fibrils through electrostatic interactions are initially removed by 
exhaustively washing amyloid rich tissue with salt solutions. The amyloid fibrils are then 
separated from the rest of the tissue components by suspension in cold, ddH20. The co-
purification of CLU with TTR in the water wash fractions suggested that CLU was not 
simply a protein associated with the amyloid through electrostatic interactions as is the 
case with amyloid P-component. Furthermore, our novel fmdings provide evidence that 
the molecular interactions of CLU with TTR in amyloid fibrils are calcium independent 
and non-ionic in nature. This is consistent with the current understanding of the 
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mechanism by which CLU functions as a chaperone by targeting exposed hydrophobic 
regions of proteins. 
The identification of CLU in amyloid deposits and the characterization of CLU as 
a component of amyloid fibrils provide a rationale for studying the functional role of 
CLU in the process of amyloidogenesis. 
11.2 Lowered Levels of Serum Clusterin in Systemic Amyloidosis 
Our analyses of CLU concentrations in amyloid patient and age-matched control 
sera showed an initial association between amyloidotic cardiomyopathy and decreased 
circulating levels of CLU. Reduced serum concentrations of CLU appeared to be more 
strongly associated with amyloidotic cardiomyopathy than amyloidosis that did not 
feature heart involvement. Moreover, lowered levels of CLU were not observed in other 
forms of cardiomyopathy, i.e. those types that did not feature amyloidosis. Our data also 
showed an inverse relationship of CLU concentrations with L VM. With these initial 
data, we sought to reproduce the serum CLU findings and expand the sample number for 
the SSA cohort. A second ELISA method was developed with several objectives in 
mind: to increase measurement accuracy, ensure that measurements were independent of 
assay artifacts, and reduce the ELISA per-plate cost by reducing the cost prohibitive 
amount of commercial recombinant CLU consumed as a standard. On second 
quantification of CLU in the same sera used in the previous study, lower concentrations 
were measured compared to the initial results; however, data trends in all groups were the 
same. Further analyses on expanded sample numbers revealed a bias in the 
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measurements associated with blood draw date. It was determined that sample storage is 
critical to accurate CLU measurement. Currently, prospective measurements of newly 
acquired serum samples are being made to accurately measure serum CLU concentrations 
in cross-sectional and longitudinal studies of SSA, A TTR, and AL patient populations. 
At this time, we cannot provide solid evidence in support of plasma CLU levels as 
a reliable biomarker for cardiac amyloid disease. However, a recent study of a small 
F AP group reported significantly decreased levels of plasma CLU in the patients 
compared to healthy controls; lower CLU concentrations were reported to be associated 
with symptomatic FAP (Magalhaes and Saraiva, 2012). Another report provides data that 
suggests a role for CLU in maintaining human arteriole endothelial function and survival 
after LC exposure (Franco et a!., 2012). In this study, the authors demonstrated that 
amyloidogenic LC induced a reduction in total endothelial cell CLU protein and mRNA 
expression, as well as secretion, in combination with increased cell death. Furthermore, 
patient isolated arterioles treated with amyloidogenic LC (800 nM) showed a reduction in 
arteriole dilation response to acetylcholine, reduced nitric oxide synthesis, and increased 
peroxynitrite production; peroxynitrite (ONOO) is a strong oxidant and a potent 
mediator of protein and DNA damage. Co-treatment with CLU ( 4 nM) preserved 
arteriole dilator responses, restored nitric oxide production, and prevented increases in 
peroxynitrite. The contribution of CLU from endothelial cells to the blood pool is 
unknown, but impaired CLU secretion in response to amyloidogenic proteins seems a 
plausible mechanism for explaining reduced plasma concentrations of CLU in systemic 
amyloidosis. 
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The CLU rs1113600 SNP is a known risk factor for Alzheimer's Disease and 
Pseudoexfoliation Syndrome, both protein misfolding and deposition diseases. We 
hypothesized that rs1113600 genotypic status may be related to the expression and/or 
secretion of CLU in patients with systemic amyloid disease. Our preliminary data 
showed an allele-dose response trend toward lower sera CLU levels in amyloid patients 
carrying the disease associated C allele. The SNP genotypes have been determined in a 
large cohort of SSA and future analyses of a correlation with serum levels of CLU in this 
group are planned. 
11.3 Chaperoning Activity of Clusterin Modulates Transthyretin Stability 
Herein, we report the first biophysical studies detailing the influence of CLU on 
TTR unfolding and stability. The results from these investigations suggest an important 
role of CLU in modulating TTR structural stability, specifically its ~-sheet secondary 
structure. Our CD data revealed that CLU has the capacity to stabilize the secondary 
structure of monomeric TTR during protein unfolding. We are able to conclude this from 
the strong activity of CLU specifically observed with monomeric (Mono, F87M/Lll OM) 
and not tetrameric (wild-type, L55P) TTR. Comparative analyses between the summed 
and observed CD spectral changes for the monomeric TTR and CLU mixtures 
(mono+CLU) showed a stabilization effect not predicted by the summed spectra. It is 
noteworthy that a delay in the higher temperature melting transition for observed 
L55P+CLU was evident by a divergence from the predicted transition at a lower 
temperature. This indicates a small but significant stabilization effect during L55P 
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unfolding, although not nearly as robust as for monomeric TTR. The wt TTR tetramer 
analyses showed no such divergence between the summed and observed spectral changes, 
demonstrating a preferential CLU stabilization effect on Mono TTR. Slight fluctuations 
at the 25°C baseline for all profiles are within experimental error, possibly due to minor 
protein concentration differences. Moreover, low temperature unfolding phases were 
identical in the CD spectra of CLU versus the mixtures of TTR tetramer and CLU 
(tetramer+CLU), but different for the Mono TTR mixture (mono+CLU) which showed a 
decreased loss of secondary structure, i.e. less changes in CD signal for CLU at 220 nm. 
Thus, it appears that CLU and TTR tetramer unfold independently of each other. This is 
supported by the observation that wild-type TTR tetramer maintains a thermal stability 
that exceeds the heating limits of our CD instrument (~98°C) . The mixture of Mono TTR 
and CLU (mono+CLU) demonstrated CD signal deviation at lower temperatures (CLU 
alone melt phase) with less unfolding during this early phase. Secondary structure in the 
mono+CLU mixture was maintained at the higher temperatures as demonstrated by the 
melt phase at 84 oc; these data indicate stabilization of TTR monomer in the presence of 
CLU. Importantly, TTR tetramer dissociation is believed to be the initial and rate 
limiting step in TTR amyloid fibril formation with monomer unfolding preceding subunit 
aggregation. The stabilization of unfolding TTR monomer by CLU supports a 
mechanism whereby CLU acting in a chaperoning capacity, interacts with TTR monomer 
and prevents a conformational conversion of misfolded TTR monomer to HMW 
oligomeric species. 
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In order to definitively demonstrate that CLU binds directly to misfolded and 
aggregated forms of TTR (and not tetramer), we used SPR biosensor detection in proof-
of-principle experiments. For these studies, the pH 2.5 tetramer dissociation assay with 
aggregation induction by NaCl addition was performed. This method was chosen in 
order to have a true 0 h aggregation time point for the monitoring of TTR oligomer 
formation. SPR biosensor chip surfaces prepared with unfolded and aggregated wild-
type TTR exhibited increased Congo red binding with a concomitant decrease in 
diflunisal binding; diflunisal is a small molecule known to bind and stabilize TTR 
tetramer. This indicated that unfolded and oligomeric forms of TTR with amyloidogenic 
structures were present and detectable by SPR. CLU bound, in a concentration-
dependent manner, to unfolded and oligomeric TTR which was coupled to the biosensor 
surfaces; a very slow dissociation phase indicated that this was a stable association of 
CLU and TTR. These data provide evidence that CLU has the capacity to bind higher 
order oligomeric species of TTR. This is the first report demonstrating the direct binding 
of CLU to misfolded proteins by SPR. 
It is apparent based on characterization studies of the TTR aggregation reaction 
that the biosensor surface TTR ligand is heterogeneous in nature. It is composed of 
various sized aggregates of TTR with multiple conformations. The precise molecular 
species of TTR recognized by CLU cannot be discerned using SPR. Another limitation 
of this study is that we were unable obtain acceptably accurate kinetic parameters for 
CLU:TTR oligomer binding. The analyses of additional concentrations of CLU were 
needed to precisely define the binding parameters, but use of the cost prohibitive CLU 
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reagent was a limiting factor. Using a highly purified form of sCLU would help to 
resolve this issue. 
11.4 Clusterin Interacts with Misfolded and Aggregated Transthyretin 
By using rTTR variants with differing structural stabilities to form amyloidogenic 
oligomers and fibrils, we were able to test the effects of sCLU on aggregation and 
fibrillogenesis, and contrast the influence of sCLU on monomeric versus tetrameric TTR. 
The stability and aggregation kinetic differences among wild-type, L55P, and Mono 
(F87M/LllOM) TTR were confirmed by thioflavin T (ThT) fluorescence measurements 
of samples from 72 h in the acid-mediated assay which correlated with relative variant 
stabilities (wt > L55P > Mono). Testing the influence of the TTR tetramer stabilizer, 
diflunisal, on L55P and monomer showed differing effects on aggregation. Diflunisal 
appeared to inhibit L55P aggregation, but enhanced monomer aggregation. By 
comparison, the presence of equimolar sCLU and TTR in samples ofL55P and monomer 
had opposite effects; sCLU appeared to enhance L55P aggregation, but suppress 
monomeric TTR aggregation. These observations imply a differential effect of sCLU on 
monomer and tetramer TTR aggregation. Baseline ThT measurements for monomeric 
TTR at 0 h were much greater than those obtained for the wild-type and L55P at 0 h, 
despite triplicate measurements performed on all samples. Thus, interpretation of these 
data is limited. 
SDS-PAGE and western blot analysis of rTTR aggregation reactions over 72 h 
demonstrated the formation of CLU:TTR high molecular weight (HMW) complexes and 
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the chaperoning character of sCLU in preventing irreversible TTR oligomerization. For 
sCLU pre-treated L55P and Mono TTR, the decrease in HMW-1 (- 250-500 kDa) and 
TTR band tetramer and monomer intensities occurring concomitantly with increased 
HMW-2 (> 500 kDa) band intensities demonstrated the formation of sCLU:TTR HMW 
complexes. Interestingly, both L55P and Mono TTR, pre-treated with sCLU, showed a 
persistent presence and amount of monomer over time as a constant band intensity at - 14 
kDa was observed in all gel lanes. These data show that sCLU and TTR were co-
migrated as HMW aggregates when analyzed by the SDS-PAGE and immunoblot. In 
addition, sCLU pre-treatment appeared to stabilize a TTR monomer-HMW aggregate 
equilibrium. Of note, this equilibrium did not appear to include a tetrameric TTR 
intermediate at least under the conditions used in the acid-mediated fibril formation 
assay. This is the first report of sCLU preferentially stabilizing monomeric forms of TTR 
rather than tetrameric TTR under aggregation conditions. These fmdings are consistent 
with the TTR amyloid fibril formation hypothesis that proposes TTR tetramer 
dissociation as the initial step in the process. 
11.5 Clusterin Can Prevent Amyloid Fibril Formation 
Amyloid fibril formation in the presence of sCLU was investigated using the 
quantitative Congo red binding spectral shift assay. The binding of Congo red to amyloid 
structures causes a red shift in the absorbance spectrum and can be easily visualized in 
spectra normalized at 4 77 nm for graphical comparisons. Our studies demonstrated the 
ability of CLU to inhibit TTR amyloid fibril formation. 
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We determined the amount of bound Congo red in amyloid fibril suspensions 
using calculations reported by Klunk et al. Results showed that both diflunisal and sCLU 
treatments decreased the total amount of bound soluble Congo red. Although the red 
shift of the spectra for diflunisal treatments is not readily apparent from visual inspection, 
the quantitative analysis of bound soluble Congo red revealed a decreased amount. This 
lower amount of bound Congo red is due to the normalization of the data at 4 77 nm for 
graphical representation and also inclusion of light scatter absorption data at 403 nm and 
541 nm. 
11.6 Proposed Models for the Role of Clusterin in Transthyretin Amyloid 
CLU was the first extracellular chaperone to be identified, and extensive 
investigations over the past decade have shown that it has a chaperoning function similar 
to small heat shock proteins such as aS-crystallin (Humphreys et al., 1999; Wilson and 
Easterbrook-Smith, 2000; Wilson et al. , 2008; Wyatt and Wilson, 2010; Wyatt et al., 
2011; Wyatt et a!., 2009; Yerbury et a/., 2007). The binding of CLU to exposed 
hydrophobic regions of misfolded proteins has been demonstrated in vitro for various 
amyloidogenic precursor proteins. Yerbury et al. (2007) demonstrated the ability of CLU 
to prevent amyloid formation with eight different amyloidogenic proteins through 
specific binding to prefibrillar amyloid structures; however, TTR and LC were not 
examined in these studies. 
In addition, high molecular weight aggregate formation of CLU chaperone: client 
complexes has been characterized in vitro, with an estimated CLU:client stoichiometry of 
202 
1:2 (Wyatt et al., 2009). We note that the ability of CLU to prevent amyloid formation 
changes in a concentration dependent manner as CLU has been shown to promote 
fibrillogenesis under appropriate conditions (Yerbury et al., 2007). When the 
amyloidogenic substrate is present in a large molar excess, CLU appears to enhance 
fibrillogenesis and is a component of the insoluble aggregates (Y erbury et al., 2007). 
Considering this concentration-dependent biphasic effect, it has been posited that CLU 
can stabilize misfolded protein conformations; by maintaining the exposure of normally 
buried hydrophobic regions on the amyloidogenic protein, CLU may augment fibril 
formation (Wilson et al., 2008). Thus, there is no way to know a priori whether the CLU 
we have observed in amyloid deposits is present because of a failed response to prevent 
aggregation or as part of the pathophysiologic process. 
The process of TTR amyloid fibril formation begins with tetramer dissociation to 
monomer. This initial step, thought to be the rate limiting step, is important in our 
interpretation of the experimental data presented herein and in defining a role for CLU in 
the TTR amyloid hypothesis. Our data supports a mechanism where both unfolded TTR 
monomer and HMW oligomeric species are chaperoned by CLU to prevent amyloid fibril 
formation (Figure 51). The complex milieu of the in vivo amyloidosis pathology is 
difficult to reproduce in experimental models. Our biochemical experiments support a 
solution-based interaction model that could mirror the chaperoning activity of CLU in the 
bloodstream with misfolded forms of TTR. This process may be overwhelmed in the 
systemic amyloid diseases leading to changing ratios of CLU:client, e.g. CLU:TTR. 
CLU binding and stabilization ofHMW oligomeric species without adequate removal 
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Figure 51. Clusterin and transthyretin amyloid hypothesis. 
The mechanism of CLU binding to TTR, stabilization of TTR monomer, and inhibition 
of Congophillic amyloid fibrils is depicted here in terms of the stages of the TTR amyloid 
hypothesis. Arrows indicate the points at which CLU has been shown, by our studies, to 
actively recognize and bind TTR in vitro. CLU interactions at these points, early in the 
misfolding stages, inhibit both protofibril and fibril formation as noted in the Congo red 
binding data presented. 
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from the circulation could lead to co-deposition of these complexes in amyloid deposits 
and contribute to a decrease in plasma concentrations of CLU (Figure 52B). 
Although this was not assessed in the present study, prolonged and/or robust 
tissue remodeling may also lead to sequestration of CLU from the circulation as dynamic 
structural changes take place in both the extracellular matrix and amyloid deposits 
(Figure 52C). These enzymatic modifications to deposited fibrils could generate newly 
exposed regions of hydrophobicity to which circulating CLU binds. Similarly, CLU-
bound amyloid may represent not only a failed attempt at removal of circulating 
amyloidogenic proteins, but also a stabilization effect of fragmented fibrils generated by 
protease activity during tissue remodeling when the microenvironment equilibrium of 
CLU:amyloid is decreased (Figure 52C). 
11.7 Summary 
Results from the studies presented herein suggest a potentially pathological role 
of CLU in SSA, ATTR, and AL types of amyloidosis. We have demonstrated the 
presence of CLU in cardiac amyloid deposits composed of TTR and LC by 
immunohistochemical and immunogold techniques. The use of CLU as a biomarker in 
systemic amyloidosis is yet to be fully determined, but continuing studies on both serum 
levels and genetic associations remain important areas of investigation. Biophysical and 
biochemical experimental data provided evidence that CLU has the ability to chaperone 
misfolding of TTR by binding to and stabilizing monomeric and oligomeric TTR species, 
and inhibiting amyloid fibril formation. Our presentation of the role ofCLU in the TTR 
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Figure 52. Model for the role of clusterin in amyloid fibril formation. 
Our mechanistic model for how circulating CLU may become deposited with amyloid 
fibrils in tissues. In the absence of CLU, HMW aggregates become incorporated into 
tissue fibrils through fibril extension (A). The disequilibrium between the CLU and the 
amyloidogenic protein may cause CLU-TTR HMW complexes to be incorporated (B). In 
addition, enzymatic activity on tissue fibrils could expose regions of hydrophobicity to 
which circulating CLU binds. 
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amyloid hypothesis is congruent with the current understanding of both TTR and CLU 
biochemical properties and supports the molecular model of CLU as a ubiquitous 
extracellular chaperone for amyloidogenic proteins. 
11.8 Future Directions 
The high yield purification method of CLU from human serum described in this 
thesis provided a robust and cost effective tool for the study TTR and CLU interactions. 
This true biological source of CLU ensures that in vivo post-translational glycosylation, 
key to chaperoning function, are present on CLU; likewise, experiments with sCLU are 
more likely to yield results that closely parallel the in vivo situation. The combined use 
of sCLU and rTTR proteins from expression systems that yield replicates of the in vivo 
proteins will allow further biophysical and biochemical characterizations of CLU :TTR 
interactions during amyloid fibril formation. Thermal stress-induced secondary structural 
changes in monomeric TTR were shown to be modulated by CLU. Extended monitoring 
of similar TTR unfolding processes under acidic stress conditions is necessary to confirm 
the same phenomenon. Simultaneous light scatter data recorded during CD kinetic 
studies will allow observation of TTR aggregation to correlate this process with 
secondary structural changes. These studies could be useful for monitoring tetramer 
unfolding and secondary structural changes in the presence ofCLU. 
While these research studies used SPR to demonstrate direct binding between 
CLU and misfolded TTR, this technique could generate much more powerful data and 
allows a unique platform for the investigation of TTR or LC amyloid aggregation. It is 
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proposed that SPR be used for more accurately defining the CLU binding kinetics to 
misfolded and oligomeric forms of TTR. Additionally, SPR should be used to monitor 
the polymerization of TTR or LC on the surface of a biosensor chip. Molecular modeling 
of TTR polymerization sensorgrams would define the TTR oligomerization process in 
novel ways. The mass dependent kinetic data and label free environment provides an 
advantage over other aggregation detection methods, e.g. ThT and Congo red. It would 
then be plausible to test pharmacological chaperones or small molecules stabilizers, and 
protein therapeutics to block the polymerization process using a direct detection platform. 
One such protein therapeutic to test could be derived from a peptide sequence of CLU 
shown to be responsible for chaperoning properties. 
Testing of the amyloid fibril enzymatic digest model depicted in Figure 52C 
should also be pursued. Amyloid fibrils generated in vitro, then exposed to various 
enzyme mixtures with small molecule enzyme inhibitors, co-factor chelating agents, and 
molecular chaperones like CLU, could test the plausibility of this model. Fragmented 
amyloid fibrils also generate a unique reagent for subsequent cell culture and mouse 
model studies that could help answer the question: What would happen if amyloid fibril 
deposits were dissolved in vivo? Cellular responses to these potentially cytotoxic species 
are important in the development of therapeutic strategies aimed at "dissolving" amyloid 
deposits in tissues like the heart as a way to ameliorate symptomatic restrictive 
cardiomyopathy. If toxic effects were observed due to fibril dissolution in vivo, the use 
of a combination therapy, such as a pharmacologic chaperone mimetic of CLU to 
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sequester HMW amyloid fragments, might prove useful as a safe and effective treatment 
for patients with systemic amyloidosis. 
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